<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>Subtitle 18 HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/10.18/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/10.18/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|10|18|"/>
    <meta itemprop="doc-type" content="container" data-document=""/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="10|18" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="http://regs.maryland.gov//us/md/exec/comar/10.18"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="Subtitle 18 HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) | Library of Maryland Regulations"/>
    <meta property="og:image" content="http://regs.maryland.gov//us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/10.18/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/10.18/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10" data-search-heading="">
                  <a href="/us/md/exec/comar/10" title="Title 10 MARYLAND DEPARTMENT OF HEALTH">Title 10 MARYLAND DEPARTMENT OF HEALTH</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|18" data-search-heading="">
                  <span title="Subtitle 18 HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)">Subtitle 18 HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="10|18">
              <div class="tuf-authenticate">
                <h1 class="h__title--small" id="/us/md/exec/comar/10.18">Subtitle 18 HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)</h1>
                <h2 id="/us/md/exec/comar/10.18.01" data-order="|10|18|01|" data-ref-path="10|18|01" class="h__chapter">Chapter 01 Maryland AIDS Drug Assistance Program: Temporary Assistance Program</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: March 28, 2016 (43:6 Md. R. 408)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.01.02#B" title="">Regulation .02B</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.01.04#B" title="">Regulation .04B</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.01.05#B" title="">Regulation .05B</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§2-104(b), 2-104(j), 2-105(a), and 18-102(a), Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.18.01.01" data-order="|10|18|01|.01|" data-ref-path="10|18|01|.01" class="h__section">.01 Purpose.</h3>
                <p>The purpose of the Maryland AIDS Drug Assistance Program’s Temporary Assistance Program is to provide short term assistance to individuals with Human Immunodeficiency Virus (HIV) who:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.01#A">A.</span> Need HIV drugs and other products;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.01#B">B.</span> Have an application for Medical Assistance or Low-Income Subsidy pending; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.01#C">C.</span> Are considered likely to have their application approved.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.01.02" data-order="|10|18|01|.02|" data-ref-path="10|18|01|.02" class="h__section">.02 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(1)">(1)</span> “Acquired immunodeficiency syndrome (AIDS)” means the medical condition caused by the Human Immunodeficiency Virus.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(2)">(2)</span> “Agent” means a case manager, licensed social worker, registered nurse, or any other related professional that assists an individual in submitting an application to the Temporary Assistance Program.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(3)">(3)</span> “Applicant” means an individual on whose behalf an application has been submitted to the Temporary Assistance Program and whose eligibility status for the Temporary Assistance Program has not yet been determined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(4)">(4)</span> “Department” means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(5)">(5)</span> “Drug” means an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease licensed by the U.S. Food and Drug Administration, and covered by the Maryland AIDS Drug Assistance Program as specified in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.04" title=".04 Covered Services.">COMAR 10.18.06.04</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(6)">(6)</span> “Enrollment period” means the period of time a recipient may receive Temporary Assistance Program benefits.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(7)">(7)</span> “Health care practitioner” means any individual licensed to prescribe U.S. Food and Drug Administration-approved drugs or other products in the state in which they practice.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(8)">(8)</span> “Human immunodeficiency virus (HIV)” means the virus that causes AIDS.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(9)">(9)</span> “Low-Income Subsidy (LIS)” means the federal program available under the Medicare Part D prescription drug program and Medicare advantage plans that assists persons who have limited income to pay for the cost of premiums, deductibles, and copayments.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(10)">(10)</span> “Maryland AIDS Drug Assistance Program (MADAP)” means the program administered by the Department that provides services specified in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.04" title=".04 Covered Services.">COMAR 10.18.06.04</a> for enrolled recipients.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(11)">(11)</span> “Medical Assistance” has the meaning specified in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.24.02" title=".02 Definitions.">COMAR 10.09.24.02</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(12)">(12)</span> “Open formulary” means all U.S. Food and Drug Administration-approved prescription medications and related devices that are not on the list of excluded drugs and other products maintained by the Department per <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.04" title=".04 Covered Services.">COMAR 10.18.06.04</a>-1.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(13)">(13)</span> “Recipient” means an individual who is enrolled in the Temporary Assistance Program.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(14)">(14)</span> “Resident” means an individual:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(14)(a)">(a)</span> Who is living in the State voluntarily with the intention of making it that individual’s home and not for a temporary purpose; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(14)(b)">(b)</span> For whom any temporary absence from the State is coupled with an intent to return so as not to interrupt the continuity of residence.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.02#B(15)">(15)</span> “Temporary Assistance Program (TAP)” means the program administered by the Department that provides short term MADAP services as specified in <a class="internal-link " href="/us/md/exec/comar/10.18.01.05" title=".05 Covered Services.">Regulation .05 of this chapter</a> for low income eligible individuals.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.01.03" data-order="|10|18|01|.03|" data-ref-path="10|18|01|.03" class="h__section">.03 Eligibility.</h3>
                <p>To be eligible for benefits, an individual shall meet the following criteria:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.03#A">A.</span> Be a resident of Maryland;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.03#B">B.</span> Be infected with HIV; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.03#C">C.</span> Have a pending application to Medical Assistance or LIS.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.01.04" data-order="|10|18|01|.04|" data-ref-path="10|18|01|.04" class="h__section">.04 Application and Enrollment.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A">A.</span> Application.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(1)">(1)</span> The agent of the applicant shall submit a completed TAP application to the Department on the form designated by the Department that includes:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(1)(a)">(a)</span> Responses to all applicable questions; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(1)(b)">(b)</span> A copy of the completed application or other verifiable documentation for Medical Assistance or LIS enrollment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(2)">(2)</span> The agent of the applicant or the applicant may voluntarily withdraw the application at any time without prejudice.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(3)">(3)</span> The Department shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(3)(a)">(a)</span> Review and process a TAP application by the end of the first business day following receipt;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(3)(b)">(b)</span> Approve a TAP application if the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(3)(b)(i)">(i)</span> TAP application is complete;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(3)(b)(ii)">(ii)</span> Applicant is determined to be eligible; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(3)(b)(iii)">(iii)</span> Department is able to ascertain that the applicant will likely be found eligible for Medical Assistance or LIS;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(3)(c)">(c)</span> Issue a client identification number if the TAP application is approved;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(3)(d)">(d)</span> Disapprove a TAP application if the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(3)(d)(i)">(i)</span> TAP application is incomplete; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(3)(d)(ii)">(ii)</span> Agent of the applicant fails to provide sufficient information or documentation to determine eligibility; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#A(3)(e)">(e)</span> Contact the agent of the applicant with the status of the TAP application.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#B">B.</span> Enrollment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#B(1)">(1)</span> A recipient shall be approved for coverage beginning the first day of the month in which the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#B(1)(a)">(a)</span> TAP application was received; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#B(1)(b)">(b)</span> Recipient will need access to medications through TAP.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.04#B(2)">(2)</span> Benefits shall end on the date that a determination of Medical Assistance or LIS coverage occurs.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.01.05" data-order="|10|18|01|.05|" data-ref-path="10|18|01|.05" class="h__section">.05 Covered Services.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.05#A">A.</span> The recipient shall obtain a prescription for each drug or other product ordered for the recipient.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.05#B">B.</span> The Department shall pay for a prescription drug or other product not excluded from the open formulary if the prescription is ordered and signed by a health care practitioner for a recipient.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.01.06" data-order="|10|18|01|.06|" data-ref-path="10|18|01|.06" class="h__section">.06 Recovery of Payments.</h3>
                <p>If benefits have been incorrectly paid or another payer has been identified, the Department shall seek recovery of the amount of those payments.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.01.07" data-order="|10|18|01|.07|" data-ref-path="10|18|01|.07" class="h__section">.07 Fraud.</h3>
                <p>The Department shall pursue cases of suspected misrepresentation or fraud pursuant to <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcr&amp;section=8-503" title="">Criminal Law Article, §8-503, Annotated Code of Maryland</a>, or any other applicable statutory provision.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.01.08" data-order="|10|18|01|.08|" data-ref-path="10|18|01|.08" class="h__section">.08 Confidentiality.</h3>
                <p>Except when communicating with the parties listed in <a class="internal-link " href="/us/md/exec/comar/10.18.01.08#B" title="">§B of this regulation</a> and unless otherwise authorized by law, the agent of an applicant, or the agent of a recipient, the Department:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.08#A">A.</span> Shall keep all applicant and recipient personal information confidential;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.08#B">B.</span> May not disclose personal information kept on an applicant or recipient without written consent of the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.08#B(1)">(1)</span> Applicant;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.08#B(2)">(2)</span> Recipient;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.08#B(3)">(3)</span> Applicant’s parent or legal guardian; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.08#B(4)">(4)</span> Recipient’s parent or legal guardian;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.08#C">C.</span> Shall comply with the laws and regulations concerning the privacy and security of protected health information under:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.08#C(1)">(1)</span> Health-General Article, Title 4, Subtitle 3, Annotated Code of Maryland; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.01.08#C(2)">(2)</span> The Health Insurance Portability and Accountability Act of 1996 (HIPAA), 42 U.S.C. §§1320d et seq., as amended, the HITECH Act, 42 U.S.C. §§17932, et seq., as amended, and 45 CFR Parts 160 and 164, as amended, and their implementing regulations; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.08#D">D.</span> Shall ensure that all interactive video technology-assisted communication comply with HIPAA patient privacy and security regulations.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.01.09" data-order="|10|18|01|.09|" data-ref-path="10|18|01|.09" class="h__section">.09 Availability of Funding and Program Termination.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.09#A">A.</span> If sufficient monies are not available to fund TAP, the Department shall take the action necessary to eliminate a deficit which may include program termination.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.01.09#B">B.</span> If TAP is terminated, the Department shall provide benefits for each current recipient in accordance with <a class="internal-link " href="/us/md/exec/comar/10.18.01.04#B" title="">Regulation .04B of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.18.02" data-order="|10|18|02|" data-ref-path="10|18|02" class="h__chapter">Chapter 02 HIV and CD4+ Investigations and Case Reporting</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: February 18, 2002 (29:3 Md. R. 220)</p>
                  <p>——————</p>
                  <p>Chapter revised effective September 8, 2008 (35:18 Md. R. 1600)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.02.01" title=".01 Scope.">Regulation .01</a> amended effective May 18, 2020 (47:10 Md. R. 518</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.02.02" title=".02 Exemptions.">Regulation .02</a> amended effective May 18, 2020 (47:10 Md. R. 518)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.02.02#B" title="">Regulation .02B</a>, C amended effective March 14, 2016 (43:5 Md. R. 385)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.02.03#B" title="">Regulation .03B</a> amended effective March 14, 2016 (43:5 Md. R. 385); May 18, 2020 (47:10 Md. R. 518)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.02.06#A" title="">Regulation .06A</a> amended effective May 18, 2020 (47:10 Md. R. 518)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.02.07" title=".07 Out-of-State Laboratories.">Regulation .07</a> amended effective May 18, 2020 (47:10 Md. R. 518)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.02.08" title=".08 Responsibility of Health Officer.">Regulation .08</a> amended effective May 18, 2020 (47:10 Md. R. 518)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.02.08#C" title="">Regulation .08C</a> amended effective March 14, 2016 (43:5 Md. R. 385)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.02.09#B" title="">Regulation .09B</a> amended effective May 18, 2020 (47:10 Md. R. 518)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.02.03#B" title="">Regulation .03B</a> amended effective March 14, 2016 (43:5 Md. R. 385)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§2-104(b), 4-101, 4-102, 18-102, 18-103, 18-201.1, 18-202.1, 18-205, 18-207, and 18-215;<br/><a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gsg&amp;section=10-617" title="">State Government Article, §10-617</a>; Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.18.02.01" data-order="|10|18|02|.01|" data-ref-path="10|18|02|.01" class="h__section">.01 Scope.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#A">A.</span> This chapter establishes the requirements for:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#A(1)">(1)</span> Physician reporting of a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#A(1)(a)">(a)</span> Case of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS); and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#A(1)(b)">(b)</span> Birth of an infant whose mother has tested positive for HIV;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#A(2)">(2)</span> Institution reporting of a case of HIV or AIDS;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#A(3)">(3)</span> Laboratory reporting of a test result for HIV infection or CD4+ count; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#A(4)">(4)</span> Follow-up of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#A(4)(a)">(a)</span> A physician's report of HIV or AIDS;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#A(4)(b)">(b)</span> A physician's report of an infant whose mother has tested positive for HIV;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#A(4)(c)">(c)</span> An institution's report of HIV or AIDS; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#A(4)(d)">(d)</span> A laboratory's report of HIV infection or CD4+ count.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#B">B.</span> Except as noted in §C or D of this regulation, this chapter applies to all instances of laboratory testing of specimens from a human body for HIV infection or CD4+ count.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#C">C.</span> This chapter does not apply if the specimen from a human body is:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#C(1)">(1)</span> Not tested for HIV infection or CD4+ count;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#C(2)">(2)</span> Tested for HIV infection solely for the purpose of determining the suitability of the source individual as a prospective donor of blood, semen, or tissue;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#C(3)">(3)</span> Taken from a patient at a designated anonymous HIV test site solely for the purpose of performing an anonymous HIV test;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#C(4)">(4)</span> Tested for HIV or CD4+ count as part of research conducted by an institution within Maryland under the following conditions:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#C(4)(a)">(a)</span> All personal identifiers are removed from the specimen before testing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#C(4)(b)">(b)</span> The specimen cannot be linked to the individual from whom the specimen was taken;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#C(4)(c)">(c)</span> The result cannot be linked to the individual from whom the specimen was taken; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#C(4)(d)">(d)</span> The research protocol has been approved by an institutional review board;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#C(5)">(5)</span> Tested for HIV or CD4+ count as part of research conducted under a research protocol approved by an institutional review board of an institution located outside of Maryland;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#C(6)">(6)</span> Taken from a patient known to reside outside of the United States; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#C(7)">(7)</span> Tested for HIV or CD4+ count as part of a research project that has been approved under <a class="internal-link " href="/us/md/exec/comar/10.18.02.02" title=".02 Exemptions.">Regulation .02 of this chapter</a> for an exemption.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.01#D">D.</span> If the director of a medical laboratory has submitted one report of HIV infection from a patient as required under <a class="internal-link " href="/us/md/exec/comar/10.18.02.06" title=".06 Responsibilities of Laboratory Directors.">Regulation .06 of this chapter</a> and another specimen from the same patient shows evidence of HIV infection, it is not necessary for the director to submit another report of HIV infection for the patient.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.02.02" data-order="|10|18|02|.02|" data-ref-path="10|18|02|.02" class="h__section">.02 Exemptions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#A">A.</span> Qualifications for Exemption. A research project that meets both of the following criteria may be eligible for exemption from the HIV reporting requirements of <a class="internal-link " href="/us/md/exec/comar/10.18.02.06" title=".06 Responsibilities of Laboratory Directors.">Regulation .06 of this chapter</a>:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#A(1)">(1)</span> The research project has been approved by an institutional review board; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#A(2)">(2)</span> The research:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#A(2)(a)">(a)</span> Is intended to determine the safety or effectiveness of a vaccine that would produce immunity against HIV; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#A(2)(b)">(b)</span> Is not primarily intended to provide medical treatment to participants.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#B">B.</span> Application for Exemption. The principal investigator of a research project shall submit all of the following documents to the Department in order to apply for an exemption:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#B(1)">(1)</span> A copy of the research protocol approved by the institutional review board of the institution conducting the research; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#B(2)">(2)</span> A copy of the notice stating that the protocol has been approved by the institutional review board of the institution conducting the research.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#C">C.</span> Approval.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#C(1)">(1)</span> The Director of the Infectious Disease Prevention and Health Services Bureau or the Director’s designee shall review the application submitted under <a class="internal-link " href="/us/md/exec/comar/10.18.02.02#B" title="">§B of this regulation</a> to determine whether the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#C(1)(a)">(a)</span> Application is complete; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#C(1)(b)">(b)</span> Research protocol meets the criteria specified in <a class="internal-link " href="/us/md/exec/comar/10.18.02.02#A" title="">§A of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#C(2)">(2)</span> If the application is complete and the research protocol meets the specified criteria, the Director shall grant an exemption from the requirements set forth in <a class="internal-link " href="/us/md/exec/comar/10.18.02.06" title=".06 Responsibilities of Laboratory Directors.">Regulation .06 of this chapter</a> for any specimen tested for HIV infection or CD4+ lymphocyte count under the research project approved for exemption.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#C(3)">(3)</span> The Director shall mail written notification to the applicant of an exemption under this regulation within 30 days of receipt of the application, stating whether the exemption:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#C(3)(a)">(a)</span> Has been approved;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#C(3)(b)">(b)</span> Has been denied and the reason for the denial; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#C(3)(c)">(c)</span> Cannot be processed until further information is provided to the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#D">D.</span> Responsibilities of the Principal Investigator. If a research project is granted an exemption under <a class="internal-link " href="/us/md/exec/comar/10.18.02.02#C" title="">§C of this regulation</a>, the principal investigator of the research project shall send to each laboratory to which specimens collected under the research protocol will be sent to be tested for HIV or CD4+ count a copy of the notification from the Director issued pursuant to <a class="internal-link " href="/us/md/exec/comar/10.18.02.02#C(3)(a)" title="">§C(3)(a) of this regulation</a> to verify that the project has been exempted from the reporting requirements of <a class="internal-link " href="/us/md/exec/comar/10.18.02.06" title=".06 Responsibilities of Laboratory Directors.">Regulation .06 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#E">E.</span> Scope of Exemption.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#E(1)">(1)</span> Except as indicated in <a class="internal-link " href="/us/md/exec/comar/10.18.02.02#E(2)" title="">§E(2) of this regulation</a>, an exemption approved under <a class="internal-link " href="/us/md/exec/comar/10.18.02.02#C" title="">§C of this regulation</a> does not relieve the principal investigator, a laboratory director, or another individual from a reporting requirement contained in Health-General Article, §18-201.1, 18-202.1, 18-205, or 18-207, Annotated Code of Maryland, or <a class="internal-link " href="/us/md/exec/comar/10.18.02.06" title=".06 Responsibilities of Laboratory Directors.">Regulation .06 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#E(2)">(2)</span> A principal investigator, laboratory director, or other individual is not required to report positive HIV test results, CD4+ counts less than 200 per cubic millimeter, or both, if the test is done as part of the research project and the individual tested:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#E(2)(a)">(a)</span> Meets the criteria for participation in the research project set forth in the research protocol submitted under <a class="internal-link " href="/us/md/exec/comar/10.18.02.02#B(1)" title="">§B(1) of this regulation</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.02#E(2)(b)">(b)</span> Has signed an informed consent form agreeing to participate in the research project.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.02.03" data-order="|10|18|02|.03|" data-ref-path="10|18|02|.03" class="h__section">.03 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(1)">(1)</span> "Acquired immunodeficiency syndrome (AIDS)" has the meaning stated in Health-General Article, §§18-201.1(a) and 18-202.1(b), Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(2)">(2)</span> "Anonymous" means that a patient does not use the patient's name as identification and can only be identified through use of a code.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(3)">(3)</span> "Assigned laboratory number" means a number assigned to a laboratory by the Department for use in filing reports of HIV infection or CD4+ count.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(4)">(4)</span> "Case" means an individual who has:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(4)(a)">(a)</span> Been clinically diagnosed as having HIV or AIDS; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(4)(b)">(b)</span> Laboratory evidence of being infected by HIV.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(5)">(5)</span> "Clinical material" means:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(5)(a)">(a)</span> An organism isolated from a clinical specimen;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(5)(b)">(b)</span> Material derived or prepared from a clinical specimen in which evidence of a communicable disease has been identified or detected; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(5)(c)">(c)</span> If neither §B(6)(a) or (b) of this regulation is available, material from an individual already held by the medical laboratory, in the following order of preference:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(5)(c)(i)">(i)</span> A patient specimen;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(5)(c)(ii)">(ii)</span> Nucleic acid; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(5)(c)(iii)">(iii)</span> Other laboratory material.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(6)">(6)</span> "Clinical or infection control practitioner" means a physician, infection control nurse, physician assistant, nurse practitioner, or other clinical staff designated by the administrative head of an institution to report under Health-General Article, §18-202.1, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(7)">(7)</span> "Department" means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(8)">(8)</span> "Designated anonymous HIV test site" means an HIV counseling and testing site designated by the Department as a site where a patient may have an anonymous HIV test.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(9)">(9)</span> "Drug" means a drug that has been:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(9)(a)">(a)</span> Licensed by the United States Food and Drug Administration (FDA); or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(9)(b)">(b)</span> Approved by the FDA as an investigational new drug.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(10)">(10)</span> "Exemption" means a research project meeting certain criteria, with the result that no reporting is required under this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(11)">(11)</span> "Health officer" means the health officer in each of the 23 counties and the Commissioner of Health in Baltimore City or the duly designated representative of the health officer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(12)">(12)</span> "Human immunodeficiency virus (HIV)" has the meaning stated in Health-General Article, §§18-201.1(a) and 18-202.1(b), Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(13)">(13)</span> "Institution" means an entity that employs an individual licensed to practice osteopathy or medicine by the State.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(14)">(14)</span> "Institutional review board" means a group of individuals designated by an institution in compliance with 45 CFR Part 46 to review the use of human subjects in proposed research.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(15)">(15)</span> "Laboratory examination order" means the written document signed by a physician or other authorized individual that specifies one or more laboratory examinations to be performed in regard to a specified patient.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(16)">(16)</span> "Newborn HIV exposure" means a newborn infant whose mother has tested positive for HIV infection.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(17)">(17)</span> "Physician" means an individual licensed to practice osteopathy or medicine by the State or the physician's designee working under the supervision of the physician.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.03#B(18)">(18)</span> "Secretary" means the Secretary of Health or the Secretary's designee.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.02.04" data-order="|10|18|02|.04|" data-ref-path="10|18|02|.04" class="h__section">.04 Physician Responsibility.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.04#A">A.</span> A physician shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.04#A(1)">(1)</span> Report a case of HIV or AIDS or newborn HIV exposure for a patient under the physician's care to the health officer within 48 hours, by phone or in writing on a form provided by the Secretary; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.04#A(2)">(2)</span> Include the information requested on the form.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.04#B">B.</span> A physician may not transmit information to the health officer or the Secretary about a case of HIV or AIDS or newborn HIV exposure by facsimile or another electronic method unless directed by the Secretary to submit the information by electronic method.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.04#C">C.</span> A physician authorized to order laboratory examinations shall include all of the following information on the written laboratory examination order for a test covered by this chapter:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.04#C(1)">(1)</span> Name, date of birth, race, ethnicity, and gender of the patient;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.04#C(2)">(2)</span> Street address, city, state, and zip code of the patient's residence; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.04#C(3)">(3)</span> Name, address, and telephone number of the physician ordering the test.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.04#D">D.</span> A physician who reports a case of HIV or AIDS or a newborn HIV exposure or orders a laboratory examination for a test covered by this chapter shall make available to the health officer or the Secretary the information necessary to compile an HIV/AIDS case report as set forth in Health-General Article, §18-207, Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.04#E">E.</span> A physician working in an institution required to report as set forth in Health-General Article, §18-202.1, Annotated Code of Maryland, is not required to report an HIV or AIDS case if the administrative head of the institution has designated an individual clinical or infection control practitioner or a specific set of clinical or infection control practitioners other than the physician to be responsible for reporting on behalf of all clinical and infection control practitioners in the facility, as set forth in <a class="internal-link " href="/us/md/exec/comar/10.18.02.05" title=".05 Responsibilities of Clinical and Infection Control Practitioners in Institutions.">Regulation .05 of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.02.05" data-order="|10|18|02|.05|" data-ref-path="10|18|02|.05" class="h__section">.05 Responsibilities of Clinical and Infection Control Practitioners in Institutions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.05#A">A.</span> A clinical or infection control practitioner working in an institution required to report as set forth in Health-General Article, §18-202.1, Annotated Code of Maryland, shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.05#A(1)">(1)</span> Report a case of HIV or AIDS under the care of the institution to the health officer within 48 hours, by phone or in writing on a form provided by the Secretary; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.05#A(2)">(2)</span> Include the information requested on the form.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.05#B">B.</span> A clinical or infection control practitioner may not transmit to the health officer or the Secretary information about a case of HIV or AIDS by facsimile or another electronic method unless directed by the Secretary to submit the information by electronic method.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.05#C">C.</span> A clinical or infection control practitioner who reports a case of HIV or AIDS shall make available to the health officer or the Secretary the information necessary to compile an HIV/AIDS case report as defined in Health-General Article, §18-207, Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.05#D">D.</span> The administrative head of an institution required to report as set forth in Health-General Article, §18-202.1, Annotated Code of Maryland, may designate an individual clinical or infection control practitioner or a specific set of clinical or infection control practitioners who shall be responsible for reporting on behalf of all clinical and infection control practitioners in the facility.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.05#E">E.</span> A clinical or infection control practitioner working in an institution required to report as defined in Health-General Article, §18-202.1, Annotated Code of Maryland, is not required to report HIV or AIDS cases if the administrative head of the institution has designated a different individual clinical or infection control practitioner or specific set of clinical or infection control practitioners who shall be responsible for reporting on behalf of all clinical practitioners in the facility.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.02.06" data-order="|10|18|02|.06|" data-ref-path="10|18|02|.06" class="h__section">.06 Responsibilities of Laboratory Directors.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A">A.</span> Except as provided in Regulations .01C and .02 of this chapter, the director of a medical laboratory shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A(1)">(1)</span> Submit a report to the health officer for the jurisdiction where the laboratory is located, within 48 hours after an examination of a specimen from a human body shows one of the following:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A(1)(a)">(a)</span> A positive result on a test designed to confirm in a sample the presence of HIV infection in accordance with Health-General Article, §18-207(b)(1), Annotated Code of Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A(1)(b)">(b)</span> A test result showing a level of HIV viral load in an individual not known to be HIV negative; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A(1)(c)">(c)</span> A CD4+ count in an individual not known to be HIV negative;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A(2)">(2)</span> Use the form provided by the Department in making the report required under <a class="internal-link " href="/us/md/exec/comar/10.18.02.06#A(1)" title="">§A(1) of this regulation</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A(3)">(3)</span> Include all of the following information in the report required under <a class="internal-link " href="/us/md/exec/comar/10.18.02.06#A(1)" title="">§A(1) of this regulation</a>:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A(3)(a)">(a)</span> Name and address of laboratory or assigned laboratory number;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A(3)(b)">(b)</span> Date the specimen was obtained from the patient;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A(3)(c)">(c)</span> Type and result of laboratory test, that is, HIV infection, HIV viral load, or CD4+ count;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A(3)(d)">(d)</span> Name, date of birth, race, ethnicity, and gender of the patient;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A(3)(e)">(e)</span> Street address, city, state, and zip code of the patient's residence;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A(3)(f)">(f)</span> Name of the physician authorizing the laboratory examination; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A(3)(g)">(g)</span> Address and telephone number of the physician authorizing the laboratory examination; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#A(4)">(4)</span> Contact the physician authorizing the laboratory examination to obtain any of the information, as required by <a class="internal-link " href="/us/md/exec/comar/10.18.02.06#A(3)" title="">§A(3) of this regulation</a>, that is not provided on the laboratory examination order.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#B">B.</span> A laboratory director may not transmit to the health officer or the Secretary information about a case of HIV or AIDS by facsimile or another electronic method unless directed by the Secretary to submit the information by electronic method.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#C">C.</span> The laboratory director shall, at the request of the Secretary, make available to the Secretary any remaining clinical material from tested individuals.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.06#D">D.</span> This regulation does not relieve a physician of the duty to report as set forth in Health-General Article, §§18-201.1 and 18-202.1, Annotated Code of Maryland.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.02.07" data-order="|10|18|02|.07|" data-ref-path="10|18|02|.07" class="h__section">.07 Out-of-State Laboratories.</h3>
                <p>An out-of-State laboratory that holds a permit to operate issued by Maryland and performs HIV or CD4+ tests shall submit the report required under <a class="internal-link " href="/us/md/exec/comar/10.18.02.06" title=".06 Responsibilities of Laboratory Directors.">Regulation .06 of this chapter</a> to the Secretary.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.02.08" data-order="|10|18|02|.08|" data-ref-path="10|18|02|.08" class="h__section">.08 Responsibility of Health Officer.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.08#A">A.</span> This regulation establishes requirements for follow-up by the health officer of a report of HIV or AIDS or newborn HIV exposure or laboratory report of HIV infection or CD4+ count.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.08#B">B.</span> This regulation does not supplant or otherwise modify the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.08#B(1)">(1)</span> Physician's obligation to report a case of HIV or AIDS or newborn HIV exposure under Health-General Article, §18-201.1, Annotated Code of Maryland, and <a class="internal-link " href="/us/md/exec/comar/10.18.02.04" title=".04 Physician Responsibility.">Regulation .04 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.08#B(2)">(2)</span> Clinical or infection control practitioner's obligation to report a case of HIV or AIDS under Health-General Article, §18-202.1, Annotated Code of Maryland, and <a class="internal-link " href="/us/md/exec/comar/10.18.02.05" title=".05 Responsibilities of Clinical and Infection Control Practitioners in Institutions.">Regulation .05 of this chapter</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.08#B(3)">(3)</span> Laboratory director's obligation to report a test result of HIV infection or CD4+ count under Health-General Article, §18-205, Annotated Code of Maryland, and <a class="internal-link " href="/us/md/exec/comar/10.18.02.06" title=".06 Responsibilities of Laboratory Directors.">Regulation .06 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.08#C">C.</span> Upon receipt of a report from a physician pursuant to <a class="internal-link " href="/us/md/exec/comar/10.18.02.04" title=".04 Physician Responsibility.">Regulation .04 of this chapter</a>, a clinical or infection control practitioner pursuant to <a class="internal-link " href="/us/md/exec/comar/10.18.02.05" title=".05 Responsibilities of Clinical and Infection Control Practitioners in Institutions.">Regulation .05 of this chapter</a>, or a laboratory director pursuant to <a class="internal-link " href="/us/md/exec/comar/10.18.02.06" title=".06 Responsibilities of Laboratory Directors.">Regulation .06 of this chapter</a>, the health officer shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.08#C(1)">(1)</span> Determine whether the case of HIV, the case of AIDS, or the newborn HIV exposure has been reported previously;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.08#C(2)">(2)</span> Complete the case investigation if the patient has HIV or AIDS or is a newborn HIV exposure and the case of HIV or the case of AIDS or the newborn HIV exposure has not been reported previously;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.08#C(3)">(3)</span> Submit the HIV/AIDS case report as set forth in Health-General Article, §18-207, Annotated Code of Maryland, to the Department if the case of HIV or the case of AIDS or the newborn HIV exposure has not been reported previously; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.08#C(4)">(4)</span> Take action as specified in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.04" title="Chapter 04 Disease Control">COMAR 10.18.04</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.08#D">D.</span> A health officer may not transmit to the Secretary information about a case of HIV or AIDS by facsimile or another electronic method unless directed by the Secretary to submit the information by electronic method.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.02.09" data-order="|10|18|02|.09|" data-ref-path="10|18|02|.09" class="h__section">.09 Record Maintenance and Confidentiality.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.09#A">A.</span> A person that submitted a report of HIV or AIDS or newborn HIV exposure shall make available to the health officer or the Secretary the information necessary to compile an HIV/AIDS case report, according to Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.02.04" title=".04 Physician Responsibility.">.04</a>—<a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.02.06" title=".06 Responsibilities of Laboratory Directors.">.06</a> of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.09#B">B.</span> Except for a designated anonymous HIV test site, a person that ordered the laboratory examination shall make available to the health officer or the Secretary the information necessary to compile an HIV/AIDS case report, according to Regulations .04 and .05 of this chapter, upon receipt of one of the following:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.09#B(1)">(1)</span> A positive result on a test designed to confirm in a sample the presence of HIV infection in accordance with Health-General Article, §18-207(b)(1), Annotated Code of Maryland;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.09#B(2)">(2)</span> The report that an HIV viral load test was performed on an individual not known to be HIV negative; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.09#B(3)">(3)</span> A CD4+ count on an individual not known to be HIV negative.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.02.09#C">C.</span> Confidentiality.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.09#C(1)">(1)</span> A report required under this chapter is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.09#C(1)(a)">(a)</span> Confidential;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.09#C(1)(b)">(b)</span> Not open to public inspection;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.09#C(1)(c)">(c)</span> Not a medical record under Health-General Article, Title 4, Subtitle 3, Annotated Code of Maryland; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.02.09#C(1)(d)">(d)</span> Subject to the confidentiality requirements of Health-General Article, Title 4, Subtitle 1, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.09#C(2)">(2)</span> The reports and any proceedings, records, or files relating to the reports required under this chapter are not discoverable and are not admissible in evidence in any civil action.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.02.09#C(3)">(3)</span> Section C(1) of this regulation does not apply to a disclosure by the Secretary to another governmental agency performing its lawful duties pursuant to State or federal law where the Secretary determines that the agency to whom the information is disclosed will maintain the confidentiality of the disclosure.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.18.03" data-order="|10|18|03|" data-ref-path="10|18|03" class="h__chapter">Chapter 03 AIDS Investigations and Case Reporting</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: February 18, 2002 (29:3 Md. R. 220)</p>
                  <p>Regulation .03B amended effective March 14, 2016 (43:5 Md. R. 385)</p>
                  <p>Regulation .04C amended effective March 14, 2016 (43:5 Md. R. 385)</p>
                  <p>——————</p>
                  <p>Regulations .01—.05 repealed effective May 18, 2020 (47:10 Md. R. 518)</p>
                </section>
                <h2 id="/us/md/exec/comar/10.18.04" data-order="|10|18|04|" data-ref-path="10|18|04" class="h__chapter">Chapter 04 Disease Control</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: February 18, 2002 (29:3 Md. R. 220)</p>
                  <p>Regulations .01 — .03 repealed effective April 24, 2017 (44:8 Md. R. 403)</p>
                </section>
                <h2 id="/us/md/exec/comar/10.18.05" data-order="|10|18|05|" data-ref-path="10|18|05" class="h__chapter">Chapter 05 Maryland AIDS Drug Assistance Program: Eligibility</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date:</p>
                  <p>Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.01" title=".01 Definitions.">.01</a>—.15 adopted as an emergency provision effective November 27, 2002 (29:25 Md. R. 1979); adopted permanently effective February 17, 2003 (30:3 Md. R. 180)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.01#B" title="">Regulation .01B</a> amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.02" title=".02 Eligibility.">Regulation .02</a> amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.03#B" title="">Regulation .03B</a>, C amended as an emergency provision effective August 11, 2004 (31:18 Md. R. 1348); amended permanently effective October 11, 2004 (31:20 Md. R. 1485)</p>
                  <p>Regulation .03C amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.05" title=".05 Reconsideration and Appeal.">Regulation .05</a> amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.05#A" title="">Regulation .05A</a> amended as an emergency provision effective August 11, 2004 (31:18 Md. R. 1348); amended permanently effective October 11, 2004 (31:20 Md. R. 1485)</p>
                  <p>Regulation .05E amended as an emergency provision effective November 14, 2003 (30:24 Md. R. 1737); amended permanently effective February 16, 2004 (31:3 Md. R. 207)</p>
                  <p>Regulation .06C amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.07" title=".07 Fraud.">Regulation .07</a> repealed as an emergency provision effective January 1, 2014 (41:4 Md. R. 298); repealed permanently effective May 26, 2014 (41:10 Md. R. 561)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.08#A" title="">Regulation .08A</a> amended as an emergency provision effective January 1, 2014 (41:4 Md. R. 298); amended permanently effective May 26, 2014 (41:10 Md. R. 561)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.08#B" title="">Regulation .08B</a> amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p>Regulation .09C adopted effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p>Regulation .11 amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p>Regulation .15A amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p>——————</p>
                  <p>Chapter revised effective March 28, 2016 (43:6 Md. R. 408)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.01#B" title="">Regulation .01B</a> amended effective May 20, 2019 (46:10 Md. R. 488); October 14, 2024 (51:20 Md. R. 899)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.02#D" title="">Regulation .02D</a> amended effective October 14, 2024 (51:20 Md. R. 899)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.02#D" title="">Regulation .02D</a>, E amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.03" title=".03 Application and Enrollment.">Regulation .03</a> amended effective October 14, 2024 (51:20 Md. R. 899)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.03#B" title="">Regulation .03B</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.04#A" title="">Regulation .04A</a>, D amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.09#B" title="">Regulation .09B</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <h3>Authority</h3>
                  <p>Health General Article, §§2-104(b) and(i), 2-105(a) and (b), and 18-102(a), Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.18.05.01" data-order="|10|18|05|.01|" data-ref-path="10|18|05|.01" class="h__section">.01 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(1)">(1)</span> “Acquired Immunodeficiency Syndrome (AIDS)” means the medical condition caused by the Human Immunodeficiency Virus.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(2)">(2)</span> “Applicant” means an individual who has submitted an application to the Maryland AIDS Drug Assistance Program and whose eligibility status for the Maryland AIDS Drug Assistance Program has not yet been determined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(3)">(3)</span> “Department” means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(4)">(4)</span> “Disenroll” means to end Maryland AIDS Drug Assistance Program benefits.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(5)">(5)</span> “Drug” means an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease licensed by the U.S. Food and Drug Administration and covered by the Maryland AIDS Drug Assistance Program as specified in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.04" title=".04 Covered Services.">COMAR 10.18.06.04</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(6)">(6)</span> “Enrolled in MADAP” means that an applicant has been approved to receive Maryland AIDS Drug Assistance Program benefits.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(7)">(7)</span> “Gross household income” means the income derived from sources provided in <a class="internal-link " href="/us/md/exec/comar/10.18.05.02#E" title="">Regulation .02E of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(8)">(8)</span> “Health care practitioner” means any individual licensed to prescribe U.S. Food and Drug Administration-approved drugs or other products in the state in which they practice.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(9)">(9)</span> “Human Immunodeficiency Virus (HIV)” means the virus that causes AIDS.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(10)">(10)</span> “Maryland AIDS Drug Assistance Program (MADAP)” means the program administered by the Department that provides services specified in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.04" title=".04 Covered Services.">COMAR 10.18.06.04</a> for enrolled recipients.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(11)">(11)</span> “Medical Assistance” has the meaning stated in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.24.02" title=".02 Definitions.">COMAR 10.09.24.02</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(12)">(12)</span> “Recipient” means an individual who is enrolled in MADAP.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(13)">(13)</span> “Resident” means an individual:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(13)(a)">(a)</span> Who is living in the State voluntarily with the intention of making it that individual’s home and not for a temporary purpose; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(13)(b)">(b)</span> For whom any temporary absence from the State is coupled with an intent to return so as not to interrupt the continuity of the residence.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.01#B(14)">(14)</span> “Verification of eligibility” means the information a recipient provides to the Department to confirm that the recipient is still eligible to receive MADAP benefits according to <a class="internal-link " href="/us/md/exec/comar/10.18.05.03#B(1)(a)" title="">Regulation .03B(1)(a) of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.05.02" data-order="|10|18|05|.02|" data-ref-path="10|18|05|.02" class="h__section">.02 Eligibility.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#A">A.</span> Except when an individual is enrolled in Medical Assistance but does not have prescription coverage assistance, an individual who is eligible for Medical Assistance is not eligible for MADAP.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#B">B.</span> To be eligible for benefits, an individual shall meet the following criteria:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#B(1)">(1)</span> Residency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#B(2)">(2)</span> Medical; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#B(3)">(3)</span> Financial.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#C">C.</span> Residency Criteria. To meet the residency criteria the individual shall be a resident of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#D">D.</span> Medical Criteria. To meet the medical criteria the individual shall be infected with HIV as verified by the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E">E.</span> Financial Criteria.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(1)">(1)</span> To meet the financial criteria the individual shall have a projected gross household income less than or equal to 500 percent of the Federal Poverty Level Guidelines as updated annually in the Federal Register by the U.S. Department of Health and Human Services under authority of 42 U.S.C. §9902(2).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(2)">(2)</span> Projected gross household income shall be determined based on what can reasonably be expected to be received during the 12-month period beginning with the month in which the completed application is filed or verification of eligibility is submitted.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(3)">(3)</span> Gross household income includes income derived from:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(3)(a)">(a)</span> Wages and salaries, including tips;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(3)(b)">(b)</span> Net income from self-employment or business;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(3)(c)">(c)</span> Unemployment income;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(3)(d)">(d)</span> Social security payments, including disability payments;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(3)(e)">(e)</span> Alimony;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(3)(f)">(f)</span> Retirement income;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(3)(g)">(g)</span> Pension income;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(3)(h)">(h)</span> Investment income;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(3)(i)">(i)</span> Rental income; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(3)(j)">(j)</span> Other taxable income, such as prizes, awards, and gambling winnings.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(4)">(4)</span> Gross household income under this chapter does not include income derived from:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(4)(a)">(a)</span> Child support;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(4)(b)">(b)</span> Gifts;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(4)(c)">(c)</span> Supplemental Social Security Income;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(4)(d)">(d)</span> Veterans’ disability payments;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(4)(e)">(e)</span> Workers’ compensation; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.02#E(4)(f)">(f)</span> Proceeds from loans, such as student loans, home equity loans, or bank loans.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.05.03" data-order="|10|18|05|.03|" data-ref-path="10|18|05|.03" class="h__section">.03 Application and Enrollment.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A">A.</span> Application.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(1)">(1)</span> Applicant.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(1)(a)">(a)</span> An applicant shall submit a completed application to the Department on the form designated by the Department that includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(1)(a)(i)">(i)</span> Responses to all required fields and applicable questions; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(1)(a)(ii)">(ii)</span> Supporting documentation related to residency, medical, and financial eligibility criteria.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(1)(b)">(b)</span> An applicant may voluntarily withdraw the application at any time without prejudice.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(1)(c)">(c)</span> An applicant may submit a new application at any time.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(2)">(2)</span> The Department shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(2)(a)">(a)</span> Approve the application if the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(2)(a)(i)">(i)</span> Application is complete; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(2)(a)(ii)">(ii)</span> Applicant is determined to be eligible;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(2)(b)">(b)</span> Disapprove the application if the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(2)(b)(i)">(i)</span> Application is incomplete;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(2)(b)(ii)">(ii)</span> Applicant fails to provide sufficient information or documentation to determine eligibility; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(2)(b)(iii)">(iii)</span> Applicant provides the appropriate documentation but is determined ineligible; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#A(2)(c)">(c)</span> Provide the applicant with written notice of the final disposition of the application.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#B">B.</span> Enrollment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#B(1)">(1)</span> If the Department requests it, a recipient shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#B(1)(a)">(a)</span> Attest to continuing eligibility:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#B(1)(b)">(b)</span> Submit a completed verification of eligibility form; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#B(1)(c)">(c)</span> Provide supporting documentation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#B(2)">(2)</span> A recipient’s MADAP benefits shall be suspended, effective at the end of the month following the month the verification of eligibility is due, if the recipient fails to attest to eligibility for MADAP.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#B(3)">(3)</span> The Department shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#B(3)(a)">(a)</span> Enroll an applicant who has been determined eligible with the stipulation that eligibility must be verified as requested by the Department;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#B(3)(b)">(b)</span> Establish enrollment in MADAP beginning on the first day of the month in which the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#B(3)(b)(i)">(i)</span> Department approves the application; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#B(3)(b)(ii)">(ii)</span> Recipient will need to access medications through MADAP;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#B(3)(c)">(c)</span> Redetermine eligibility if the Department receives information that may affect eligibility; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.05.03#B(3)(d)">(d)</span> Send any relevant verification of eligibility forms to the recipient at least 45 calendar days before the forms are due to be submitted to the Department.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.05.04" data-order="|10|18|05|.04|" data-ref-path="10|18|05|.04" class="h__section">.04 Changes in Eligibility and Disenrollment.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#A">A.</span> A recipient shall notify the Department within 10 business days of a change in:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#A(1)">(1)</span> Availability of third-party payment for services covered under MADAP;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#A(2)">(2)</span> Gross household income; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#A(3)">(3)</span> Address.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#B">B.</span> If a change reported in <a class="internal-link " href="/us/md/exec/comar/10.18.05.04#A" title="">§A of this regulation</a> results in a recipient no longer qualifying for MADAP, the Department shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#B(1)">(1)</span> Determine the recipient ineligible for MADAP; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#B(2)">(2)</span> Disenroll the recipient.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#C">C.</span> The notice of intended action, which notifies the recipient of the disenrollment, shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#C(1)">(1)</span> Be mailed to the recipient at least 15 business days before the effective date of disenrollment;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#C(2)">(2)</span> Include an explanation of the action;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#C(3)">(3)</span> Cite the regulation supporting the action; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#C(4)">(4)</span> Explain the right of the recipient to request reconsideration or an appeal of the decision.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#D">D.</span> If the recipient is determined to be ineligible before the next verification of eligibility is due to be submitted to the Department because of a change in eligibility, the disenrollment shall be the earlier of:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#D(1)">(1)</span> The date on which the recipient’s next verification of eligibility is due to be submitted to the Department; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#D(2)">(2)</span> The first day of the month that is at least 15 calendar days after the date of the notice of ineligibility for MADAP benefits.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.04#E">E.</span> If the recipient’s Medical Assistance coverage is pending or active, the recipient shall be disenrolled, as determined by the Department.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.05.05" data-order="|10|18|05|.05|" data-ref-path="10|18|05|.05" class="h__section">.05 Reconsideration and Appeal.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.05#A">A.</span> An applicant or recipient who has been notified by the Department of ineligibility for or disenrollment from MADAP benefits may request reconsideration of the decision by submitting additional supporting documentation or information to the Department within 30 business days of notification.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.05#B">B.</span> If an applicant or recipient submits a timely request for reconsideration, the Department shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.05#B(1)">(1)</span> Review all additional supporting documentation, within 5 business days of the Department’s receipt of the request for reconsideration; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.05#B(2)">(2)</span> Issue a final decision in writing to the applicant or recipient.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.05#C">C.</span> If an applicant or recipient is dissatisfied with the final decision of the Department, the applicant or recipient may appeal the reconsideration by requesting in writing for a hearing with the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.05#D">D.</span> The Office of Administrative Hearings shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.05#D(1)">(1)</span> Conduct a hearing according to the procedures set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/28.02.01" title="Chapter 01 Rules of Procedure">COMAR 28.02.01</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.05#D(2)">(2)</span> Hold a hearing to review the decision within 45 days of the postmarked date on the letter requesting a hearing; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.05#D(3)">(3)</span> Issue a decision in writing to the applicant or recipient.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.05.06" data-order="|10|18|05|.06|" data-ref-path="10|18|05|.06" class="h__section">.06 Recovery of Payments.</h3>
                <p>If MADAP benefits have been incorrectly paid or another payer has been identified, the Department shall seek recovery of the amount of those payments.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.05.07" data-order="|10|18|05|.07|" data-ref-path="10|18|05|.07" class="h__section">.07 Fraud.</h3>
                <p>The Department shall pursue cases of suspected misrepresentation or fraud pursuant to <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcr&amp;section=8-503" title="">Criminal Law Article, §8-503, Annotated Code of Maryland</a>, or any other applicable statutory provision.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.05.08" data-order="|10|18|05|.08|" data-ref-path="10|18|05|.08" class="h__section">.08 Confidentiality.</h3>
                <p>Unless otherwise authorized by law, the Department:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.08#A">A.</span> Shall keep all applicant and recipient personal information confidential;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.08#B">B.</span> May not disclose personal information kept on an applicant or recipient without written consent of the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.08#B(1)">(1)</span> Applicant;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.08#B(2)">(2)</span> Recipient;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.08#B(3)">(3)</span> Applicant’s parent or legal guardian; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.08#B(4)">(4)</span> Recipient’s parent or legal guardian;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.08#C">C.</span> Shall comply with the laws and regulations concerning the privacy and security of protected health information under:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.08#C(1)">(1)</span> Health-General Article, Title 4, Subtitle 3, Annotated Code of Maryland; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.08#C(2)">(2)</span> The Health Insurance Portability and Accountability Act of 1996 (HIPAA), 42 U.S.C. §§1320d et seq., as amended, the HITECH Act, 42 U.S.C. §§17932, et seq., as amended, and 45 CFR Parts 160 and 164, as amended, and their implementing regulations; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.08#D">D.</span> Shall ensure that all interactive video technology-assisted communication comply with HIPAA patient privacy and security regulations.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.05.09" data-order="|10|18|05|.09|" data-ref-path="10|18|05|.09" class="h__section">.09 Availability of Funding and Program Termination.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.09#A">A.</span> If sufficient monies are not available to fund MADAP, the Department shall take the action necessary to eliminate a deficit which may include MADAP termination.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.05.09#B">B.</span> If MADAP is terminated the Department shall provide benefits for each current recipient until the earlier of:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.09#B(1)">(1)</span> The date on which the next verification of eligibility is due to be submitted to the Department; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.05.09#B(2)">(2)</span> Six months from the date MADAP is terminated.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.18.06" data-order="|10|18|06|" data-ref-path="10|18|06" class="h__chapter">Chapter 06 Maryland AIDS Drug Assistance Program: Pharmacy Services</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date:</p>
                  <p>Regulations <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.01" title=".01 Definitions.">.01</a>—<a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.12" title=".12 Availability of Funding and Program Termination.">.12</a> adopted as an emergency provision effective November 27, 2002 (29:25 Md. R. 1979); adopted permanently effective February 17, 2003 (30:3 Md. R. 180)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.01#B" title="">Regulation .01B</a> amended as an emergency provision effective August 11, 2004 (31:18 Md. R. 1348); amended permanently effective October 11, 2004 (31:20 Md. R. 1485)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.01#B" title="">Regulation .01B</a> amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.04" title=".04 Covered Services.">Regulation .04</a> repealed and new Regulation .04 adopted as an emergency provision effective August 11, 2004 (31:18 Md. R. 1348); adopted permanently effective October 11, 2004 (31:20 Md. R. 1485)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.04#B" title="">Regulation .04B</a> amended as an emergency provision effective November 14, 2003 (30:24 Md. R. 1737); amended permanently effective February 16, 2004 (31:3 Md. R. 207)</p>
                  <p>Regulation .04C adopted effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.04-1" title=".04-1 Formulary.">Regulation .04-1</a> adopted as an emergency provision effective August 11, 2004 (31:18 Md. R. 1348); adopted permanently effective October 11, 2004 (31:20 Md. R. 1485)</p>
                  <p>Regulation .04-2 adopted as an emergency provision effective August 11, 2004 (31:18 Md. R. 1348); adopted permanently effective October 11, 2004 (31:20 Md. R. 1485)</p>
                  <p>Regulation .04-2 amended as an emergency provision effective January 1, 2014 (41:4 Md. R. 298); amended permanently effective May 26, 2014 (41:10 Md. R. 561)</p>
                  <p>Regulation .04-2 amended effective September 15, 2014 (41:18 Md. R. 1010)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.05#A" title="">Regulation .05A</a> amended as an emergency provision effective February 20, 2007 (34:7 Md. R. 694); amended permanently effective June 18, 2007 (34:12 Md. R. 1067)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.05#B" title="">Regulation .05B</a> amended as an emergency provision effective January 1, 2014 (41:4 Md. R. 298); amended permanently effective May 26, 2014 (41:10 Md. R. 561)</p>
                  <p>Regulation .06A amended as an emergency provision effective November 14, 2003 (30:24 Md. R. 1737); amended permanently effective February 16, 2004 (31:3 Md. R. 207)</p>
                  <p>Regulation .06A amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.12#A" title="">Regulation .12A</a> amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p>——————</p>
                  <p>Chapter revised effective March 28, 2016 (43:6 Md. R. 408)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.01#B" title="">Regulation .01B</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.03#A" title="">Regulation .03A</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.04#B" title="">Regulation .04B</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.04-1" title=".04-1 Formulary.">Regulation .04-1</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p>Regulation .04-2 repealed effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.05#B" title="">Regulation .05B</a> amended effective May 20, 2019 (46:10 Md. R. 488), October 14, 2024 (51:20 Md. R. 899)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.08" title=".08 Recovery and Reimbursement.">Regulation .08</a> amended effective October 14, 2024 (51:20 Md. R. 899)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.09#A" title="">Regulation .09A</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.10" title=".10 Appeal Procedures.">Regulation .10</a> amended effective October 14, 2024 (51:20 Md. R. 899)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.11#B" title="">Regulation .11B</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <h3>Authority</h3>
                  <p>Health General Article, §§2-104(b) and(i), 2-105(a) and (b), and 18-102(a), Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.18.06.01" data-order="|10|18|06|.01|" data-ref-path="10|18|06|.01" class="h__section">.01 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B(1)">(1)</span> “Acquired Immunodeficiency Syndrome (AIDS)” means the medical condition caused by the Human Immunodeficiency Virus.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B(2)">(2)</span> “Department” means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B(3)">(3)</span> “Drug” means an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease licensed by the U.S. Food and Drug Administration and covered by the Maryland AIDS Drug Assistance Program as specified in <a class="internal-link " href="/us/md/exec/comar/10.18.06.04" title=".04 Covered Services.">Regulation .04 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B(4)">(4)</span> “Enrolled in MADAP” means that an applicant has been approved to receive Maryland AIDS Drug Assistance Program benefits.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B(5)">(5)</span> “Health care practitioner” means any individual licensed to prescribe U.S. Food and Drug Administration-approved drugs or other products in the state in which they practice.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B(6)">(6)</span> “Human Immunodeficiency Virus (HIV)” means the virus that causes AIDS.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B(7)">(7)</span> “Maryland AIDS Drug Assistance Program (MADAP)” means the program administered by the Department that provides services specified in <a class="internal-link " href="/us/md/exec/comar/10.18.06.04" title=".04 Covered Services.">Regulation .04 of this chapter</a> for enrolled recipients.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B(8)">(8)</span> “Medical Assistance” has the meaning stated in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.24.02" title=".02 Definitions.">COMAR 10.09.24.02</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B(9)">(9)</span> “Open formulary” means all U.S. Food and Drug Administration-approved prescription medications and related devices that are not on the list of excluded drugs and other products maintained by the Department according to <a class="internal-link " href="/us/md/exec/comar/10.18.06.04-1" title=".04-1 Formulary.">Regulation .04-1 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B(10)">(10)</span> “Pharmacist” means an individual registered and licensed to practice pharmacy in the state where the prescription is filled.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B(11)">(11)</span> “Pharmacy” means an establishment or institution registered and licensed to dispense U.S. Food and Drug Administration-approved drugs or other products to the public in the state in which the establishment or institution is located.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B(12)">(12)</span> “Preauthorization” means an approval required before the dispensing of the prescription.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B(13)">(13)</span> “Prescription” means a direction, usually written by a health care provider authorized to prescribe drugs and other products and sent to the pharmacist for the preparation, dispensing, and directions for use of a drug or other product not excluded from the open formulary.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.01#B(14)">(14)</span> “Recipient” means an individual who is enrolled in MADAP.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.06.02" data-order="|10|18|06|.02|" data-ref-path="10|18|06|.02" class="h__section">.02 License Requirements.</h3>
                <p>The license requirements for participation in MADAP are the same as those for the Medical Assistance Pharmacy Services Program set forth at <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.02" title=".02 License Requirements.">COMAR 10.09.03.02</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.06.03" data-order="|10|18|06|.03|" data-ref-path="10|18|06|.03" class="h__section">.03 Conditions for Participation.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.03#A">A.</span> To participate in MADAP, a pharmacy shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.03#A(1)">(1)</span> Be enrolled in Medical Assistance, be a mail order company that accepts payments from the Department, or submit a request for exception to, and receive approval from, the Department;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.03#A(2)">(2)</span> Accept payment by the Department as payment in full for the professional services rendered and make no additional charges to the recipient or the recipient’s family;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.03#A(3)">(3)</span> Maintain records in accordance with standards established by Medical Assistance;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.03#A(4)">(4)</span> Maintain prescriptions for a minimum of 5 years and make them available for inspection, upon request, to the Department or its designee;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.03#A(5)">(5)</span> Provide services without regard to race, color, creed, age, sex, sexual orientation, gender identity, national origin, marital status, or disability; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.03#A(6)">(6)</span> Bill the recipient’s third-party insurance payer in accordance with the payer’s requirements in order to reduce the cost to be paid by the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.03#B">B.</span> A pharmacy may not:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.03#B(1)">(1)</span> Knowingly employ a person who has been disqualified from Medical Assistance; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.03#B(2)">(2)</span> Place a restriction on a recipient’s right to select a pharmacy of the recipient’s choice.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.06.04" data-order="|10|18|06|.04|" data-ref-path="10|18|06|.04" class="h__section">.04 Covered Services.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.04#A">A.</span> The recipient shall obtain a prescription for each drug or other product ordered for the recipient.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.04#B">B.</span> The Department shall pay for a prescription drug or other product not excluded from the open formulary if the prescription is ordered and signed by a health care practitioner for the recipient.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.06.04-1" data-order="|10|18|06|.04-1|" data-ref-path="10|18|06|.04-1" class="h__section">.04-1 Formulary.</h3>
                <p>The Department shall:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.04-1#A">A.</span> Maintain a list of drugs and other products excluded from the open formulary; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.04-1#B">B.</span> Make available electronically the list of drugs and other products excluded from the open formulary.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.06.05" data-order="|10|18|06|.05|" data-ref-path="10|18|06|.05" class="h__section">.05 Limitations on Covered Services.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.05#A">A.</span> A pharmacist may not dispense more than a 100-day supply of a prescribed drug or other product.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.05#B">B.</span> The Department may not pay for:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.05#B(1)">(1)</span> A drug or other product prescribed as part of a recipient’s care in a correctional institution, inpatient hospital, nursing home, or long-term care setting; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.05#B(2)">(2)</span> Drugs or other products excluded from the open formulary, unless the Department grants the recipient preauthorization.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.06.06" data-order="|10|18|06|.06|" data-ref-path="10|18|06|.06" class="h__section">.06 Preauthorization Requirement.</h3>
                <p>A pharmacist shall obtain preauthorization for each prescription or refill before dispensing a drug or other product marked as restricted.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.06.07" data-order="|10|18|06|.07|" data-ref-path="10|18|06|.07" class="h__section">.07 Payment Procedures.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.07#A">A.</span> Except as provided in §§B and C of this regulation, the Department shall pay a pharmacy in accordance with the procedures of the Medical Assistance Pharmacy Services Program set forth at <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07" title=".07 Payment Procedures.">COMAR 10.09.03.07</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.07#B">B.</span> If the Department or the recipient tells the pharmacy that the recipient has or may have third-party insurance coverage to offset some or all of the cost for services provided under MADAP, the pharmacy shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.07#B(1)">(1)</span> Bill the third-party payer the pharmacy’s usual and customary charge for the services provided; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.07#B(2)">(2)</span> Bill the Department for the difference between the pharmacy’s usual and customary charge and the anticipated third-party receipts.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.07#C">C.</span> If the recipient has third-party insurance coverage, the Department shall pay the pharmacy the difference between the pharmacy’s usual and customary charge and the anticipated third-party insurance receipts, not to exceed the amount permitted under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.07#F" title="">COMAR 10.09.03.07F</a> and G.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.07#D">D.</span> The Department shall make payments related to MADAP in accordance with any applicable policies and procedures for the administration of federal funds issued pursuant to the Ryan White HIV/AIDS Treatment Extension Act of 2009, and any subsequent modifications to the Act.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.06.08" data-order="|10|18|06|.08|" data-ref-path="10|18|06|.08" class="h__section">.08 Recovery and Reimbursement.</h3>
                <p>The Department shall follow the same procedures for recovery and reimbursement as the Medical Assistance Program in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.08" title=".08 Recovery and Reimbursement.">COMAR 10.09.03.08</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.06.09" data-order="|10|18|06|.09|" data-ref-path="10|18|06|.09" class="h__section">.09 Cause for Suspension or Removal and Imposition of Sanctions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#A">A.</span> If the Department determines that a pharmacy or the pharmacy’s employee, or both, has failed to comply with federal or State laws and regulations, the Department may:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#A(1)">(1)</span> Suspend the pharmacy from MADAP;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#A(2)">(2)</span> Withhold payment to the pharmacy; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#A(3)">(3)</span> Both.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#B">B.</span> Removal of a pharmacy or a pharmacy’s employee from Medical Assistance shall result in removal from MADAP.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#C">C.</span> The Department:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#C(1)">(1)</span> May consult with the State Board of Pharmacy regarding the actions of a pharmacy, such as:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#C(1)(a)">(a)</span> A breach of confidentiality;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#C(1)(b)">(b)</span> Refusal of service; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#C(1)(c)">(c)</span> Discrimination; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#C(2)">(2)</span> Shall consider the findings and recommendations of the State Board of Pharmacy when deciding on the imposition of a sanction as stated in <a class="internal-link " href="/us/md/exec/comar/10.18.06.09#A" title="">§A of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#D">D.</span> The Department shall give the pharmacy written notice of the Department’s intention to impose sanctions referred to in <a class="internal-link " href="/us/md/exec/comar/10.18.06.09#A" title="">§A of this regulation</a>, including:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#D(1)">(1)</span> The effective date of the proposed action;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#D(2)">(2)</span> The reason for the proposed action; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#D(3)">(3)</span> The pharmacy’s right to appeal the proposed action.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.09#E">E.</span> A pharmacy voluntarily withdrawing from MADAP or removed or suspended from MADAP according to this regulation shall notify a recipient that the pharmacy is no longer a MADAP pharmacy.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.06.10" data-order="|10|18|06|.10|" data-ref-path="10|18|06|.10" class="h__section">.10 Appeal Procedures.</h3>
                <p>A pharmacy filing an appeal shall do so in accordance with the Medical Assistance Program as set forth at <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.03.10" title=".10 Appeal Procedures.">COMAR 10.09.03.10</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.06.11" data-order="|10|18|06|.11|" data-ref-path="10|18|06|.11" class="h__section">.11 Confidentiality.</h3>
                <p>Unless otherwise authorized by law, the Department:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.11#A">A.</span> Shall keep all applicant and recipient personal information confidential;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.11#B">B.</span> May not disclose personal information kept on a recipient without written consent of the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.11#B(1)">(1)</span> Recipient; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.11#B(2)">(2)</span> Recipient’s parent or legal guardian;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.11#C">C.</span> Shall comply with the laws and regulations concerning the privacy and security of protected health information under:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.11#C(1)">(1)</span> Health-General Article, Title 4, Subtitle 3, Annotated Code of Maryland; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.06.11#C(2)">(2)</span> The Health Insurance Portability and Accountability Act of 1996 (HIPAA), 42 U.S.C. §§1320d et seq., as amended, the HITECH Act, 42 U.S.C. §§17932, et seq., as amended, and 45 CFR Parts 160 and 164, as amended, and their implementing regulations; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.11#D">D.</span> Shall ensure that all interactive video technology-assisted communication comply with HIPAA patient privacy and security regulations.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.06.12" data-order="|10|18|06|.12|" data-ref-path="10|18|06|.12" class="h__section">.12 Availability of Funding and Program Termination.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.12#A">A.</span> If sufficient monies are not available to fund MADAP, the Department shall take the action necessary to eliminate a deficit which may include MADAP termination.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.06.12#B">B.</span> If MADAP is terminated, the Department shall provide benefits for each current recipient in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.09#B" title="">COMAR 10.18.05.09B</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.18.07" data-order="|10|18|07|" data-ref-path="10|18|07" class="h__chapter">Chapter 07 Maryland AIDS Drug Assistance Program: Health Insurance (MADAP-PLUS)</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: February 3, 2003 (30:2 Md. R. 76)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.07.01#B" title="">Regulation .01B</a> amended effective December 27, 2010 (37:26 Md. R. 1788); March 16, 2015 (42:5 Md. R. 486)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.07.03" title=".03 Application and Enrollment.">Regulation .03</a> amended effective December 27, 2010 (37:26 Md. R. 1788); March 16, 2015 (42:5 Md. R. 486)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.07.04" title=".04 Covered Services.">Regulation .04</a> amended as an emergency provision effective January 1, 2014 (41:4 Md. R. 298); amended permanently effective May 26, 2014 (41:10 Md. R. 561)</p>
                  <p>Regulation .04D amended as an emergency provision effective August 11, 2004 (31:18 Md. R. 1348); amended permanently effective October 11, 2004 (31:20 Md. R. 1485)</p>
                  <p>Regulation .04D, E amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.07.06#D" title="">Regulation .06D</a> amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.07.10#A" title="">Regulation .10A</a> amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p>Regulation .16A amended effective March 16, 2015 (42:5 Md. R. 486)</p>
                  <p>——————</p>
                  <p>Chapter revised effective March 28, 2016 (43:6 Md. R. 408)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.07.01#B" title="">Regulation .01B</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.07.02" title=".02 Eligibility.">Regulation .02</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.07.03#C" title="">Regulation .03C</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.07.04" title=".04 Covered Services.">Regulation .04</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.07.06#F" title="">Regulation .06F</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.07.07#B" title="">Regulation .07B</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.07.11#B" title="">Regulation .11B</a> amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <h3>Authority</h3>
                  <p>Health-General Article, §§2-104(b) and(i) and 2-105(a) and (b), Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.18.07.01" data-order="|10|18|07|.01|" data-ref-path="10|18|07|.01" class="h__section">.01 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#B(1)">(1)</span> “Acquired Immunodeficiency Syndrome (AIDS)” means the medical condition caused by the Human Immunodeficiency Virus.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#B(2)">(2)</span> “Applicant” means an individual who has submitted an application to the Maryland AIDS Drug Assistance Program—Plus and whose eligibility status for the Maryland AIDS Drug Assistance Program—Plus has not yet determined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#B(3)">(3)</span> “Core medical services” means a set of direct health care services as specified by the Ryan White Care Act Part B Program administered by the U.S. Health Resource and Services Administration.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#B(4)">(4)</span> “Department” means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#B(5)">(5)</span> “Enrolled in MADAP” means that an applicant has been approved to receive Maryland AIDS Drug Assistance Program benefits.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#B(6)">(6)</span> “Health care provider” means an individual licensed to provide core medical services in the state where services are rendered.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#B(7)">(7)</span> “Human immunodeficiency virus (HIV)” means the virus that causes AIDS.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#B(8)">(8)</span> “Maryland AIDS Drug Assistance Program (MADAP)” means the program administered by the Department that provides services specified in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.04" title=".04 Covered Services.">COMAR 10.18.06.04</a> for enrolled recipients.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#B(9)">(9)</span> “Maryland AIDS Drug Assistance Program—Plus (MADAP-Plus)” means the program administered by the Department to pay insurance premiums, copays, coinsurance, and deductibles for drugs and core medical services.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#B(10)">(10)</span> “Medical Assistance” has the meaning stated in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.09.24.02" title=".02 Definitions.">COMAR 10.09.24.02</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#B(11)">(11)</span> “Open formulary” means all U.S. Food and Drug Administration-approved prescription medications and related devices that are not on the list of excluded drugs and other products maintained by the Department according to <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.06.04" title=".04 Covered Services.">COMAR 10.18.06.04</a>-1.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#B(12)">(12)</span> “Recipient” means an individual who is enrolled in MADAP-Plus.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.01#B(13)">(13)</span> “Verification of eligibility” means the information a recipient provides to the Department to confirm that the recipient is still eligible to receive MADAP benefits according to <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.03#B(1)(a)" title="">COMAR 10.18.05.03B(1)(a)</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.07.02" data-order="|10|18|07|.02|" data-ref-path="10|18|07|.02" class="h__section">.02 Eligibility.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.02#A">A.</span> To be eligible for MADAP-Plus coverage, an individual shall be:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.02#A(1)">(1)</span> Enrolled in MADAP; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.02#A(2)">(2)</span> Receiving or eligible to receive health insurance and prescription drug coverage.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.02#B">B.</span> An individual who is eligible for employer-sponsored health insurance with a prescription drug formulary that includes antiretroviral medications may not receive premium assistance unless the individual is:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.02#B(1)">(1)</span> Enrolled in the employer-sponsored health plan; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.02#B(2)">(2)</span> Paying 50 percent or more of the total monthly health insurance premiums.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.07.03" data-order="|10|18|07|.03|" data-ref-path="10|18|07|.03" class="h__section">.03 Application and Enrollment.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.03#A">A.</span> An applicant shall apply in the manner set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.03#A" title="">COMAR 10.18.05.03A</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.03#B">B.</span> A recipient and the Department shall meet the enrollment responsibilities set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.03#B" title="">COMAR 10.18.05.03B</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.03#C">C.</span> The duration of the recipient’s enrollment in MADAP-Plus may not extend beyond the duration of the recipient’s enrollment in MADAP.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.07.04" data-order="|10|18|07|.04|" data-ref-path="10|18|07|.04" class="h__section">.04 Covered Services.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.04#A">A.</span> The Department shall pay for health and prescription plan premiums with a prescription drug formulary that includes antiretroviral medications.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.04#B">B.</span> Within the limits established by the Department and in accordance with policy guidance issued by the Health Resources and Services Administration, the Department:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.04#B(1)">(1)</span> Shall pay for copays, coinsurance, and deductibles for drugs; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.04#B(2)">(2)</span> May pay for copays, coinsurance, and deductibles associated with core medical services.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.07.05" data-order="|10|18|07|.05|" data-ref-path="10|18|07|.05" class="h__section">.05 Changes in Eligibility and Disenrollment.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.05#A">A.</span> A recipient shall inform the Department of a change in eligibility as set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.05.04#A" title="">COMAR 10.18.05.04A</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.05#B">B.</span> If a change reported in <a class="internal-link " href="/us/md/exec/comar/10.18.07.05#A" title="">§A of this regulation</a> results in a recipient no longer qualifying for MADAP-Plus, the Department shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.05#B(1)">(1)</span> Determine the recipient ineligible for MADAP-Plus; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.05#B(2)">(2)</span> Disenroll the recipient.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.05#C">C.</span> If a MADAP-Plus recipient is disenrolled from MADAP, the recipient is automatically disenrolled from MADAP-Plus.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.07.06" data-order="|10|18|07|.06|" data-ref-path="10|18|07|.06" class="h__section">.06 Reconsideration and Appeal.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.06#A">A.</span> An applicant or recipient who has been notified by the Department of disenrollment or ineligibility for MADAP-Plus benefits may request reconsideration of the decision by submitting additional supporting documentation or information to the Department within 30 business days of notification.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.06#B">B.</span> If an applicant or recipient submits a timely request for reconsideration, the Department shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.06#B(1)">(1)</span> Review all additional supporting documentation, within five business days of the Department’s receipt of the request for reconsideration; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.06#B(2)">(2)</span> Issue a final decision in writing to the applicant or recipient.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.06#C">C.</span> If an applicant or recipient is dissatisfied with the final decision of the Department, the applicant or recipient may appeal the reconsideration by requesting in writing for a hearing with the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.06#D">D.</span> The Office of Administrative Hearings shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.06#D(1)">(1)</span> Conduct a hearing according to the procedures set forth in <a class="internal-link no-wrap" href="/us/md/exec/comar/28.02.01" title="Chapter 01 Rules of Procedure">COMAR 28.02.01</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.06#D(2)">(2)</span> Hold a hearing to review the decision within 45 days of the postmarked date on the letter requesting a hearing; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.06#D(3)">(3)</span> Issue a decision in writing to the applicant or recipient.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.06#E">E.</span> The Department shall pay any health insurance plan or prescription drug plan costs due pending a decision by the Office of Administrative Hearings.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.06#F">F.</span> If the final decision finds in favor of the Department, the Department shall, upon the date of the decision, cease paying the health insurance costs allowed under this chapter and seek recovery in accordance with <a class="internal-link " href="/us/md/exec/comar/10.18.07.08" title=".08 Recovery of Payments.">Regulation .08 of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.07.07" data-order="|10|18|07|.07|" data-ref-path="10|18|07|.07" class="h__section">.07 Payment Procedures.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#A">A.</span> A recipient, recipient’s representative, health care provider, insurer, employer, or health plan administrator, as applicable:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#A(1)">(1)</span> May request payment costs allowed under this chapter on behalf of the recipient according to procedures established by the Department;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#A(2)">(2)</span> Shall submit a payment request that is:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#A(2)(a)">(a)</span> An invoice for the recipient’s health or prescription drug plan insurance premium, copays, coinsurance, and deductibles for core medical services issued by an insurer, an employer, a health plan administrator, prescription drug plan administrator, or a health care provider; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#A(2)(b)">(b)</span> Submitted timely to allow for payment in accordance with §§A(3) and B(4) of this regulation; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#A(3)">(3)</span> Shall make the initial request for the payment of costs within the time frames established by the health or prescription drug insurance policy.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#B">B.</span> The Department:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#B(1)">(1)</span> Shall process a payment request as required by this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#B(2)">(2)</span> Shall inform a recipient or the recipient’s representative if an invoice is not paid;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#B(3)">(3)</span> Shall make payments in accordance with any applicable policies and procedures for the administration of federal funds issued pursuant to the Ryan White CARE Act Amendments of 1996, P. L. 104—146, and any subsequent modifications to the Act; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#B(4)">(4)</span> Shall make subsequent payments:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#B(4)(a)">(a)</span> As permitted under a health or prescription drug plan; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#B(4)(b)">(b)</span> Upon agreement between the Department and the:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#B(4)(b)(i)">(i)</span> Insurer;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#B(4)(b)(ii)">(ii)</span> Employer;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#B(4)(b)(iii)">(iii)</span> Health plan administrator;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#B(4)(b)(iv)">(iv)</span> Prescription drug plan administrator; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.07.07#B(4)(b)(v)">(v)</span> Health care provider.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.07.08" data-order="|10|18|07|.08|" data-ref-path="10|18|07|.08" class="h__section">.08 Recovery of Payments.</h3>
                <p>If MADAP-Plus payments have been incorrectly paid or another payer has been identified, the Department shall seek recovery of the amount of those payments.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.07.09" data-order="|10|18|07|.09|" data-ref-path="10|18|07|.09" class="h__section">.09 Fraud.</h3>
                <p>The Department shall pursue cases of suspected misrepresentation or fraud pursuant to <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcr&amp;section=8-503" title="">Criminal Law Article, §8-503, Annotated Code of Maryland</a>, or any other applicable statutory provision.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.07.10" data-order="|10|18|07|.10|" data-ref-path="10|18|07|.10" class="h__section">.10 Confidentiality.</h3>
                <p>Unless otherwise authorized by law, the Department:</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.10#A">A.</span> Shall keep all applicant and recipient personal information confidential;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.10#B">B.</span> May not disclose personal information kept on an applicant or recipient without the written consent of the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.10#B(1)">(1)</span> Applicant;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.10#B(2)">(2)</span> Recipient;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.10#B(3)">(3)</span> Applicant’s parent or legal guardian; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.10#B(4)">(4)</span> Recipient’s parent or legal guardian;</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.10#C">C.</span> Shall comply with the laws and regulations concerning the privacy and security of protected health information under:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.10#C(1)">(1)</span> Health-General Article, Title 4, Subtitle 3, Annotated Code of Maryland; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.10#C(2)">(2)</span> The Health Insurance Portability and Accountability Act of 1996 (HIPAA), 42 U.S.C; §§1320d et seq., as amended, the HITECH Act, 42 U.S.C. §§17932, et seq., as amended, and 45 CFR Parts 160 and 164, as amended, and their implementing regulations; and</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.10#D">D.</span> Shall ensure that all interactive video technology-assisted communication comply with HIPAA patient privacy and security regulations.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.07.11" data-order="|10|18|07|.11|" data-ref-path="10|18|07|.11" class="h__section">.11 Availability of Funding and Program Termination.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.11#A">A.</span> If sufficient monies are not available to fund MADAP-Plus, the Department shall take the action necessary to eliminate a deficit which may include MADAP-Plus termination.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.07.11#B">B.</span> If MADAP-Plus is terminated, the Department shall provide coverage for each current recipient until the earlier of:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.11#B(1)">(1)</span> The date on which the next verification of eligibility is due to be submitted to the Department; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.07.11#B(2)">(2)</span> Six months from the date MADAP-Plus is terminated.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.18.08" data-order="|10|18|08|" data-ref-path="10|18|08" class="h__chapter">Chapter 08 HIV Testing Procedures</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: February 3, 2003 (30:2 Md. R. 76)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.01#A" title="">Regulation .01A</a> amended effective December 14, 2009 (36:25 Md. R. 1954)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.01#F" title="">Regulation .01F</a> adopted effective December 14, 2009 (36:25 Md. R. 1954)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.02#B" title="">Regulation .02B</a> amended effective September 8, 2008 (35:18 Md. R. 1600); December 14, 2009 (36:25 Md. R. 1954)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.03" title=".03 Requirements for Designated Anonymous Testing Sites.">Regulation .03</a> amended effective April 13, 2015 (42:7 Md. R. 569)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.04" title=".04 Requirements for Designated Confidential Testing Sites.">Regulation .04</a> amended effective April 13, 2015 (42:7 Md. R. 569)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.05" title=".05 Denial and Reconsideration.">Regulation .05</a> amended effective April 13, 2015 (42:7 Md. R. 569)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.06" title=".06 Consent and Pretest Requirements for HIV Testing by Health Care Providers.">Regulation .06</a> amended effective December 14, 2009 (36:25 Md. R. 1954)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.06#B" title="">Regulation .06B</a> amended effective September 8, 2008 (35:18 Md. R. 1600)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.07" title=".07 Testing Requirements for Pregnant Women Receiving Prenatal Care.">Regulation .07</a> amended effective December 14, 2009 (36:25 Md. R. 1954)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.08" title=".08 Consent and Pretest Requirements for HIV Testing in Nonclinical Settings.">Regulation .08</a> amended effective December 14, 2009 (36:25 Md. R. 1954)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.10#A" title="">Regulation .10A</a>, C amended effective December 14, 2009 (36:25 Md. R. 1954)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.11" title=".11 Immunity for Health Care Providers Working with Pregnant Women.">Regulation .11</a> adopted effective June 11, 2012 (39:11 Md. R. 687)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.18.08.12" title=".12 Health Care Providers, First Responders, and Public Safety Workers — HIV Exposure.">Regulation .12</a> adopted effective June 11, 2012 (39:11 Md. R. 687)</p>
                  <p>——————</p>
                  <p>Chapter revised effective March 28, 2016 (43:6 Md. R. 408)</p>
                  <p>——————</p>
                  <p>Chapter revised effective May 7, 2018 (45:9 Md. R. 462)</p>
                  <h3>Authority</h3>
                  <p>Criminal Procedure Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-107" title="">11-107</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-117" title="">11-117</a>; Health-General Article, §§2-104(b) and(i), 2-105(a) and (b),<br/>18-102, 18-201.1, 18-202.1, 18-205, 18-207, 18-208, 18-334, 18-336—18-338, 18-338.2, 18-338.3, and 20-102; Annotated Code of Maryland</p>
                </section>
                <h3 id="/us/md/exec/comar/10.18.08.01" data-order="|10|18|08|.01|" data-ref-path="10|18|08|.01" class="h__section">.01 Scope.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#A">A.</span> Except as provided in §§C—F of this regulation, this chapter governs:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#A(1)">(1)</span> Pretest and post-test information;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#A(2)">(2)</span> Requirements for reporting and control efforts;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#A(3)">(3)</span> Requirements for informed consent; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#A(4)">(4)</span> Specific counseling for patients, including when HIV testing is performed on pregnant women as part of a prenatal care program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#B">B.</span> In cases exempt from the requirements for consent throughout this chapter, as specified in §§C—F of this regulation, it is not necessary to obtain written informed consent for HIV testing on the form approved by the Secretary.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#C">C.</span> If an HIV test is performed on an individual solely for the purpose of determining the suitability of that individual as a prospective donor of blood, semen, or tissue, the requirements for information and consent are addressed in:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#C(1)">(1)</span> Health-General Article, §18-334, Annotated Code of Maryland; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#C(2)">(2)</span> <a class="internal-link no-wrap" href="/us/md/exec/comar/10.50.01" title="Chapter 01 Tissue Banks">COMAR 10.50.01</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#D">D.</span> If an HIV test is performed on an individual as a result of a court order issued under the provisions of the Criminal Procedure Article, §§<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-107" title="">11-107</a>—<a class="internal-link no-wrap" href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gcp&amp;section=11-117" title="">11-117</a>, Annotated Code of Maryland:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#D(1)">(1)</span> The requirements for HIV testing are addressed in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.52.10" title="Chapter 10 HIV and Hepatitis C Testing of Persons Accused or Convicted, or Both, of Certain Crimes">COMAR 10.52.10</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#D(2)">(2)</span> Informed consent does not apply.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#E">E.</span> HIV testing undertaken under provisions of Health-General Article, §§18-338, 18-338.1, and 18-338.3, Annotated Code of Maryland, is not governed by this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#F">F.</span> HIV testing of specimens for research is not governed by this chapter if:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#F(1)">(1)</span> All personal identifiers have been removed from the specimen;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#F(2)">(2)</span> The specimen cannot be linked to the patient from whom the specimen was taken;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#F(3)">(3)</span> The test result cannot be linked to the patient from whom the specimen was taken; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#F(4)">(4)</span> The research protocol has been approved by an institutional review board.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.01#G">G.</span> This chapter pertains to all patients for whom a diagnostic test for the presence of HIV infection is conducted, including minors and pregnant women receiving prenatal care.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.08.02" data-order="|10|18|08|.02|" data-ref-path="10|18|08|.02" class="h__section">.02 Definitions.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(1)">(1)</span> “Acquired immunodeficiency syndrome (AIDS)” means the medical condition caused by the human immunodeficiency virus.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(2)">(2)</span> “Anonymous” means that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(2)(a)">(a)</span> A patient’s name is not used for identification; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(2)(b)">(b)</span> The patient can be identified only through use of an assigned code.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(3)">(3)</span> “Applicant” means a community based organization or other similar agency that seeks approval to become a designated human immunodeficiency virus testing site.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(4)">(4)</span> “Appropriate entity” means the Maryland Department of Health or the Baltimore City Health Department, which designate HIV testing sites in the State per Regulations .03 and .04 of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(5)">(5)</span> “Centers for Disease Control and Prevention (CDC)” means the federal Centers for Disease Control and Prevention of the federal Department of Health and Human Services.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(6)">(6)</span> “Confidential” means that a patient’s name is used as identification and that the patient’s medical records contain the patient’s name but are protected against disclosure as provided by statute.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(7)">(7)</span> “Counseling” means providing education to pregnant women on:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(7)(a)">(a)</span> The effect of a positive HIV test result on the pregnant woman and fetus concerning the risk of transmission of HIV to the fetus; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(7)(b)">(b)</span> Recognized methods of reducing the risk of transmission of HIV to the fetus during pregnancy.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(8)">(8)</span> "Department" means the Maryland Department of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(9)">(9)</span> “Designated anonymous testing site” means a human immunodeficiency virus testing site approved by the Department or the Baltimore City Health Department as a site where a patient may have an anonymous human immunodeficiency virus test using a code rather than a name for identification.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(10)">(10)</span> “Health care facility” means a facility or office where health or medical care is provided to patients by a health care provider including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(10)(a)">(a)</span> A hospital or related institution as defined in Health-General Article, §19-301, Annotated Code of Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(10)(b)">(b)</span> A freestanding medical facility as defined in Health-General Article, §19-3A-01, Annotated Code of Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(10)(c)">(c)</span> A health maintenance organization as defined in Health-General Article, §19-701, Annotated Code of Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(10)(d)">(d)</span> The Department of Public Safety and Correctional Services;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(10)(e)">(e)</span> A program approved by the Department to provide human immunodeficiency virus testing services, according to Regulations .03 and .04 of this chapter;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(10)(f)">(f)</span> A facility operated by the Department or a local health officer; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(10)(g)">(g)</span> The office of a health care provider.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(11)">(11)</span> “Health care provider” means a:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(11)(a)">(a)</span> Physician;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(11)(b)">(b)</span> Nurse;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(11)(c)">(c)</span> Licensed direct-entry midwife; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(11)(d)">(d)</span> Designee of a health care facility.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(12)">(12)</span> “Human immunodeficiency virus (HIV)” means a virus that causes AIDS.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(13)">(13)</span> “Indeterminate HIV test result” means that a test did not establish either the presence or absence of HIV infection as defined by the CDC’s laboratory criteria.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(14)">(14)</span> “Informed consent” means the voluntary permission by the patient to be tested for HIV, after the patient receives pretest information as specified in Regulations .06 and .08 of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(15)">(15)</span> "Institutional review board" means a group of individuals designated by an institution in compliance with 45 CFR 46, to review the use of human subjects in proposed research.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(16)">(16)</span> “Negative HIV test result” means the test result failed to document the presence of HIV as defined by the CDC’s laboratory criteria.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(17)">(17)</span> Nonclinical Settings.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(17)(a)">(a)</span> “Nonclinical settings” means locations:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(17)(a)(i)">(i)</span> That are not health care settings;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(17)(a)(ii)">(ii)</span> Where medical or treatment services are not provided; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(17)(a)(iii)">(iii)</span> Where selected diagnostic services and selected prevention services may be provided.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(17)(b)">(b)</span> “Nonclinical settings” may include:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(17)(b)(i)">(i)</span> Community based organizations;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(17)(b)(ii)">(ii)</span> Outreach settings; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(17)(b)(iii)">(iii)</span> Mobile vans.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(18)">(18)</span> Partner.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(18)(a)">(a)</span> “Partner” means an individual with whom one has:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(18)(a)(i)">(i)</span> Had or will have, oral, anal, or vaginal sexual contact; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(18)(a)(ii)">(ii)</span> Shared hypodermic needles or other similar drug paraphernalia.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(18)(b)">(b)</span> “Partner” includes any individual who:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(18)(b)(i)">(i)</span> Is the marriage partner of an HIV-infected patient; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(18)(b)(ii)">(ii)</span> Has been the marriage partner of the HIV-infected patient at any time within the 10-year period before the diagnosis of HIV infection.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(19)">(19)</span> “Patient” means any individual who has presented for an HIV test, whether or not the individual chooses to be tested for HIV.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(20)">(20)</span> “Positive HIV test result” means the test result has documented the presence of HIV as defined by the CDC’s laboratory criteria.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(21)">(21)</span> “Post-test information” means notifying a patient about HIV test results and providing a patient with other relevant information after an HIV test has been performed, as required by Regulations .09 and .10 of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(22)">(22)</span> “Prenatal care” means obstetric and gynecologic services performed as part of a medical care program for a pregnant woman and her unborn child, and may include:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(22)(a)">(a)</span> Screening;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(22)(b)">(b)</span> Physical examination;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(22)(c)">(c)</span> Laboratory and diagnostic testing procedures and interpretation; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(22)(d)">(d)</span> Counseling.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(23)">(23)</span> “Pretest information” means providing a patient with information before a specimen is tested for the presence of HIV infection, as required by Regulations .06 and .08 of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(24)">(24)</span> "Research" means an investigation carried out according to a protocol approved by an institutional review board.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(25)">(25)</span> "Secretary" means the Secretary of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(26)">(26)</span> “Seropositive” means that a positive HIV test result has been obtained from the test of a patient’s specimen.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(27)">(27)</span> "Specimen" means a sample of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(27)(a)">(a)</span> Blood;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(27)(b)">(b)</span> Other body fluid; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(27)(c)">(c)</span> Body tissue.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.02#B(28)">(28)</span> “Surrogate consent” means consent given by an individual who is not the patient, as permitted under Health-General Article, §5-605, Annotated Code of Maryland, and other provisions of Maryland law.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.08.03" data-order="|10|18|08|.03|" data-ref-path="10|18|08|.03" class="h__section">.03 Requirements for Designated Anonymous Testing Sites.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.03#A">A.</span> An applicant shall seek approval from an appropriate entity to become a designated anonymous testing site from the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.03#A(1)">(1)</span> Baltimore City Health Department for an applicant offering services in Baltimore City; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.03#A(2)">(2)</span> Department for an applicant offering services outside of Baltimore City.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.03#B">B.</span> An applicant that seeks approval to become a designated anonymous testing site shall request an application from the appropriate entity and submit a completed application in writing to the appropriate entity.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.03#C">C.</span> The Department or the Baltimore City Health Department shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.03#C(1)">(1)</span> Review a written request that is submitted for approval; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.03#C(2)">(2)</span> Respond in writing to the written request:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.03#C(2)(a)">(a)</span> Indicating approval or disapproval to become a designated anonymous testing site; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.03#C(2)(b)">(b)</span> Soliciting for revision and resubmission of the written request.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.08.04" data-order="|10|18|08|.04|" data-ref-path="10|18|08|.04" class="h__section">.04 Requirements for Designated Confidential Testing Sites.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.04#A">A.</span> An applicant shall seek approval from an appropriate entity to become a designated confidential testing site from the:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.04#A(1)">(1)</span> Baltimore City Health Department for an applicant offering services in Baltimore City; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.04#A(2)">(2)</span> Department for an applicant offering services outside of Baltimore City.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.04#B">B.</span> An applicant that seeks approval to become a designated confidential testing site shall request an application from the appropriate entity and submit a completed application in writing to the appropriate entity.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.04#C">C.</span> The Department or the Baltimore City Health Department shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.04#C(1)">(1)</span> Review a written request that is submitted for approval; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.04#C(2)">(2)</span> Respond in writing to the written request:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.04#C(2)(a)">(a)</span> Indicating approval or disapproval to become a designated confidential testing site; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.04#C(2)(b)">(b)</span> Soliciting for revision and resubmission of the written request.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.08.05" data-order="|10|18|08|.05|" data-ref-path="10|18|08|.05" class="h__section">.05 Denial and Reconsideration.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.05#A">A.</span> An applicant under Regulation .03 or .04 of this chapter that has a written request denied by the appropriate entity may request reconsideration of the decision:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.05#A(1)">(1)</span> By submitting the request in writing to the appropriate entity; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.05#A(2)">(2)</span> Within 30 calendar days of the date on the notice of denial.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.05#B">B.</span> If an applicant requests a reconsideration according to <a class="internal-link " href="/us/md/exec/comar/10.18.08.05#A" title="">§A of this regulation</a>, the appropriate entity shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.05#B(1)">(1)</span> Review the request for reconsideration and any supplemental documentation submitted by the applicant within 45 calendar days of the date on the letter requesting reconsideration; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.05#B(2)">(2)</span> Issue a decision in writing to the applicant.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.08.06" data-order="|10|18|08|.06|" data-ref-path="10|18|08|.06" class="h__section">.06 Consent and Pretest Requirements for HIV Testing by Health Care Providers.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#A">A.</span> General medical consent is sufficient to perform HIV testing.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#B">B.</span> Consent for HIV testing is only required to be obtained one time during a patient’s visit.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#C">C.</span> A health care provider who obtains consent for HIV testing shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#C(1)">(1)</span> Obtain consent as a part of a patient’s general consent for medical care in the same manner as for other screening and diagnostic tests;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#C(2)">(2)</span> Document all declinations of an HIV test in the medical record of the patient; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#C(3)">(3)</span> When needed, obtain:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#C(3)(a)">(a)</span> Consent from a health care agent designated per Health-General Article, §5-602, Annotated Code of Maryland; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#C(3)(b)">(b)</span> Surrogate consent per Health-General Article, §5-605 Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#D">D.</span> The general informed consent form for medical care may specify that an HIV test will be performed.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#E">E.</span> Except as provided under <a class="internal-link " href="/us/md/exec/comar/10.18.08.08" title=".08 Consent and Pretest Requirements for HIV Testing in Nonclinical Settings.">Regulation .08 of this chapter</a>, a health care provider may not be required to obtain consent for HIV testing on a separate consent form.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#F">F.</span> Pretest information, including counseling for pregnant women, shall be provided to the patient to be tested for HIV before each specimen is tested.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G">G.</span> A health care provider providing pretest information, including counseling for pregnant women, shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(1)">(1)</span> Provide HIV-specific information:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(1)(a)">(a)</span> Verbally;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(1)(b)">(b)</span> In writing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(1)(c)">(c)</span> Through video; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(1)(d)">(d)</span> Through any combination of §G(1)(a)—(c) of this regulation;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(2)">(2)</span> Provide HIV information in a manner that protects the confidentiality of the patient being tested;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(3)">(3)</span> Using layman’s terms, provide, at minimum, the following information to the patient being tested:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(3)(a)">(a)</span> That the patient is being tested for HIV;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(3)(b)">(b)</span> That the patient has the right to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(3)(b)(i)">(i)</span> Ask questions; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(3)(b)(ii)">(ii)</span> Decline the test without penalty;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(3)(c)">(c)</span> An explanation of HIV infection;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(3)(d)">(d)</span> That a negative HIV test result means that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(3)(d)(i)">(i)</span> A patient is not infected with HIV or that the test was unable to detect the presence of HIV because a patient is in the early stage of infection and has not yet developed detectable evidence of HIV infection; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(3)(d)(ii)">(ii)</span> If the patient has had any potential recent exposures, the patient should be retested within an appropriate time frame based on the type of testing used; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(3)(e)">(e)</span> That a positive HIV test result means the patient:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(3)(e)(i)">(i)</span> Is infected with HIV; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(3)(e)(ii)">(ii)</span> Will be linked with medical treatment and other supportive services;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(4)">(4)</span> Provide counseling as defined in <a class="internal-link " href="/us/md/exec/comar/10.18.08.02" title=".02 Definitions.">Regulation .02 of this chapter</a> to pregnant women;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(5)">(5)</span> Include an opportunity for the patient to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(5)(a)">(a)</span> Ask questions and receive answers about HIV and other topics described in this regulation; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(5)(b)">(b)</span> Decline an HIV test; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.06#G(6)">(6)</span> Make necessary accommodation with respect to language or disability to ensure that the patient being tested understands the information presented.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.08.07" data-order="|10|18|08|.07|" data-ref-path="10|18|08|.07" class="h__section">.07 Testing Requirements for Pregnant Women Receiving Prenatal Care.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.07#A">A.</span> As part of a health care provider’s patient acceptance procedures or protocol, a health care provider shall give a pregnant woman information on being tested for the presence of HIV as part of the woman’s prenatal care program.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.07#B">B.</span> In addition to §§C—E of this regulation, a health care provider testing a pregnant woman shall follow all requirements for pretest and post-test information as set forth in Regulations .06 and .08—.10 of this chapter as appropriate.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.07#C">C.</span> Unless a patient declines, a health care provider shall test a pregnant woman under the health care provider’s care:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.07#C(1)">(1)</span> During the first trimester of pregnancy or the first prenatal visit; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.07#C(2)">(2)</span> In the third trimester of pregnancy.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.07#D">D.</span> A health care provider who provides labor and delivery services to a pregnant woman shall offer:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.07#D(1)">(1)</span> A rapid HIV test to a pregnant woman with unknown or undocumented HIV status during labor and delivery; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.07#D(2)">(2)</span> Antiretroviral prophylaxis before receiving the results of the confirmatory test if a rapid HIV test performed during labor and delivery is positive.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.07#E">E.</span> Confidentiality.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.07#E(1)">(1)</span> HIV test results for pregnant women shall be maintained pursuant to Health-General Article, §18-338.2, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.07#E(2)">(2)</span> Except as otherwise provided in <a class="internal-link " href="/us/md/exec/comar/10.18.08.07#E(3)" title="">§E(3) of this regulation</a>, the record of an HIV test performed under this section is confidential and not discoverable or admissible in evidence in any criminal, civil, or administrative action.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.07#E(3)">(3)</span> Provided that the identity or any other information that could readily be associated with the identity of the pregnant woman is not disclosed, the results of an HIV test performed under this section may be introduced into evidence in a criminal, civil, or administrative action, including the adjudication of a workers’ compensation claim.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.08.08" data-order="|10|18|08|.08|" data-ref-path="10|18|08|.08" class="h__section">.08 Consent and Pretest Requirements for HIV Testing in Nonclinical Settings.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#A">A.</span> For HIV tests administered in nonclinical settings, as permitted in Regulations .03 and .04 of this chapter, the individual administering the HIV test shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#A(1)">(1)</span> Utilize the HIV informed consent form approved by the Secretary to document the obtainment of informed consent;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#A(2)">(2)</span> Read and explain the HIV informed consent form, through an interpreter if necessary, to anyone who cannot read or understand the form’s contents; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#A(3)">(3)</span> Obtain voluntary written informed consent from the patient before an HIV test is performed on a specimen.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#B">B.</span> A patient tested at a designated anonymous nonclinical test site, as permitted in <a class="internal-link " href="/us/md/exec/comar/10.18.08.03" title=".03 Requirements for Designated Anonymous Testing Sites.">Regulation .03 of this chapter</a>, may indicate consent by placing their assigned code on the signature line of the form approved by the Secretary to indicate written informed consent.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#C">C.</span> Pretest information shall be provided to the patient being tested before each specimen is tested.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D">D.</span> An individual providing pretest information shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(1)">(1)</span> Provide HIV-specific information:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(1)(a)">(a)</span> Verbally;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(1)(b)">(b)</span> In writing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(1)(c)">(c)</span> Through video; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(1)(d)">(d)</span> Through any combination of §D(1)(a)—(c) of this regulation based on the testing history and information needs of the patient;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(2)">(2)</span> Provide HIV information in a manner that protects the confidentiality of the patient;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)">(3)</span> Using layman’s terms, provide, at a minimum, the following information to the patient:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(a)">(a)</span> That the patient is being tested for HIV;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(b)">(b)</span> That the patient has the right to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(b)(i)">(i)</span> Ask questions; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(b)(ii)">(ii)</span> Decline the test without penalty;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(c)">(c)</span> The primary modes of HIV transmission including:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(c)(i)">(i)</span> Sexual contact without the use of condoms, other barriers, or other biomedical interventions;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(c)(ii)">(ii)</span> Injection drug use; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(c)(iii)">(iii)</span> Mother-to-child transmission;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(d)">(d)</span> Counseling as defined in <a class="internal-link " href="/us/md/exec/comar/10.18.08.02" title=".02 Definitions.">Regulation .02 of this chapter</a> to pregnant women;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(e)">(e)</span> That a negative test result means that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(e)(i)">(i)</span> A patient is not infected with HIV or that the test was unable to detect the presence of HIV because a patient is in the early stage of infection and has not yet developed detectable evidence of HIV infection; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(e)(ii)">(ii)</span> If the patient has had any potential recent exposures, that the patient should be retested within an appropriate time frame based on the type of testing used;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(f)">(f)</span> That a positive test result means the patient:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(f)(i)">(i)</span> Is infected with HIV;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(f)(ii)">(ii)</span> Will be linked with medical treatment and other supportive services; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(f)(iii)">(iii)</span> May need a confirmatory test if the preliminary positive was based on an HIV rapid test; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(3)(g)">(g)</span> Inform the patient being tested at a designated anonymous HIV test site that an assigned code will be used instead of a name;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(4)">(4)</span> Include an opportunity for the patient to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(4)(a)">(a)</span> Ask questions and receive answers about HIV infection and other topics described in this regulation; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(4)(b)">(b)</span> Decline HIV testing; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.08#D(5)">(5)</span> Make necessary accommodation with respect to language or disability to ensure that the patient understands the information presented.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.08.09" data-order="|10|18|08|.09|" data-ref-path="10|18|08|.09" class="h__section">.09 Post-Test Requirements for HIV Testing by Health Care Providers.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#A">A.</span> If a patient’s HIV test result is negative, the individual providing testing shall provide post-test information to the patient tested that includes:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#A(1)">(1)</span> That the HIV test result is negative; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#A(2)">(2)</span> The meaning of a negative result.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#B">B.</span> If a patient’s HIV test result is indeterminate, the individual providing testing shall provide post-test information to the patient in person that includes:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#B(1)">(1)</span> That the HIV test result is indeterminate;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#B(2)">(2)</span> The meaning of an indeterminate HIV test result; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#B(3)">(3)</span> A recommendation that the patient:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#B(3)(a)">(a)</span> Return in a medically appropriate time frame for another HIV test; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#B(3)(b)">(b)</span> Take precautions as if the patient’s HIV test result had been positive until the patient is retested.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C">C.</span> If a patient’s HIV test result is positive:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(1)">(1)</span> The individual providing testing shall provide post-test information to the patient in person that includes:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(1)(a)">(a)</span> That the HIV test result is positive;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(1)(b)">(b)</span> The meaning of a positive HIV test result;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(1)(c)">(c)</span> If the patient is pregnant:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(1)(c)(i)">(i)</span> How HIV infection may affect a pregnancy, fetus, or newborn;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(1)(c)(ii)">(ii)</span> That there is a potential that the newborn will have HIV infection; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(1)(c)(iii)">(iii)</span> Information regarding recognized methods of reducing the risk of transmission of HIV to the fetus; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(1)(d)">(d)</span> Information regarding the patient’s responsibility to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(1)(d)(i)">(i)</span> Notify all known sexual and needle-sharing partners of possible exposure; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(1)(d)(ii)">(ii)</span> Request assistance from the health officer in the jurisdiction to notify all known sexual and needle-sharing partners of possible exposure;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(2)">(2)</span> The health care provider shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(2)(a)">(a)</span> Ensure the patient is linked to an appropriate source of HIV medical care and support services; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(2)(b)">(b)</span> If necessary, provide the patient with information about mental health services for HIV-infected individuals;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(3)">(3)</span> For contact control, the health care provider shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(3)(a)">(a)</span> Endeavor to bring an individual with whom the patient has had potentially infectious contact to examination and, as appropriate, prophylaxis by:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(3)(a)(i)">(i)</span> Requesting the health officer to conduct a contact investigation of any case of HIV; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(3)(a)(ii)">(ii)</span> Interviewing the patient in order to ascertain the names, descriptions, addresses, telephone numbers, and email addresses of those with whom the patient has had potentially infectious contact; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(3)(b)">(b)</span> Report immediately to the health officer an individual identified as having had potentially infectious contact with a patient with a positive HIV test result;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(4)">(4)</span> A health officer shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(4)(a)">(a)</span> Investigate and notify immediately an individual reported under the provisions of <a class="internal-link " href="/us/md/exec/comar/10.18.08.09#C(3)(b)" title="">§C(3)(b) of this regulation</a>, who is within the health officer’s jurisdiction of the individual’s exposure and advise the individual to undergo a medical examination to ascertain whether the individual is infected with HIV; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(4)(b)">(b)</span> Immediately forward to the Secretary all reports of individuals who are outside the health officer’s territorial jurisdiction for referral to the health officer of the proper jurisdiction; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.09#C(5)">(5)</span> A reported individual shall, within 1 week of notification, be examined to ascertain whether the individual has been infected with HIV.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.08.10" data-order="|10|18|08|.10|" data-ref-path="10|18|08|.10" class="h__section">.10 Post-Test Requirements for HIV Testing in Nonclinical Settings.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#A">A.</span> If a patient’s HIV test result is negative, the individual providing testing shall provide post-test information to the patient tested that includes:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#A(1)">(1)</span> That the HIV test result is negative;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#A(2)">(2)</span> The meaning of a negative result; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#A(3)">(3)</span> A recommendation about whether a repeat test is advisable based on potential recent exposures and the type of test technology used.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#B">B.</span> If a patient’s HIV test result is indeterminate, the individual providing testing shall provide post-test information to the patient tested in person that includes:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#B(1)">(1)</span> That the HIV test result is indeterminate;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#B(2)">(2)</span> The meaning of an indeterminate HIV test result;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#B(3)">(3)</span> Information regarding transmission of HIV and means of preventing transmission of HIV; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#B(4)">(4)</span> A recommendation that the patient:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#B(4)(a)">(a)</span> Return in a medically appropriate time frame for another HIV test; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#B(4)(b)">(b)</span> Take precautions as if the patient’s HIV test result had been positive until the patient is retested.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C">C.</span> If a patient’s HIV test result is positive:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(1)">(1)</span> The individual providing testing shall provide post-test information to the patient tested in person that includes:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(1)(a)">(a)</span> That the HIV test result is positive;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(1)(b)">(b)</span> The meaning of a positive HIV test result;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(1)(c)">(c)</span> Information regarding transmission of HIV and means of preventing transmission of HIV;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(1)(d)">(d)</span> If the patient is pregnant;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(1)(d)(i)">(i)</span> How HIV infection may affect a pregnancy, fetus, or newborn;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(1)(d)(ii)">(ii)</span> That there is a potential that the newborn would have HIV infection; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(1)(d)(iii)">(iii)</span> Information regarding recognized methods of reducing the risk of transmission of HIV to the fetus;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(1)(e)">(e)</span> That the patient should have a medical evaluation by a physician or physician’s designee who knows that the patient is HIV positive;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(1)(f)">(f)</span> That the patient should receive ongoing health care appropriate for an HIV seropositive individual; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(1)(g)">(g)</span> Information regarding the patient’s responsibility to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(1)(g)(i)">(i)</span> Notify all known sexual and needle-sharing partners of possible exposure; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(1)(g)(ii)">(ii)</span> Request assistance from the health officer in the jurisdiction to notify all known sexual and needle-sharing partners of possible exposure;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(2)">(2)</span> The individual performing the HIV test shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(2)(a)">(a)</span> Ensure the patient is linked to an appropriate source of HIV medical care and support services including evaluation and treatment for:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(2)(a)(i)">(i)</span> Tuberculosis;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(2)(a)(ii)">(ii)</span> Hepatitis;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(2)(a)(iii)">(iii)</span> Pregnancy; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(2)(a)(iv)">(iv)</span> Sexually transmitted infections; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(2)(b)">(b)</span> If necessary, provide the patient with information about mental health services for HIV-infected individuals;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(3)">(3)</span> For contact control, the individual providing the testing shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(3)(a)">(a)</span> Request the health officer from the patient’s home jurisdiction conduct a contact investigation of any case of HIV; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(3)(b)">(b)</span> Report immediately to the health officer from the patient’s home jurisdiction any known individual identified as having had potentially infectious contact with a patient with a positive HIV test result;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(4)">(4)</span> A health officer shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(4)(a)">(a)</span> Investigate and notify immediately an individual reported under the provisions of <a class="internal-link " href="/us/md/exec/comar/10.18.08.10#C(3)(b)" title="">§C(3)(b) of this regulation</a>, who is within the health officer’s jurisdiction, of the individual’s exposure and advise the individual to undergo a medical examination to ascertain whether the individual is infected with HIV; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(4)(b)">(b)</span> Immediately forward to the Secretary all reports of individuals who are outside the health officer’s jurisdiction for referral to the health officer of the proper jurisdiction; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.10#C(5)">(5)</span> A reported individual shall, within 1 week of notification, be examined to ascertain whether the individual has been infected with HIV.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.08.11" data-order="|10|18|08|.11|" data-ref-path="10|18|08|.11" class="h__section">.11 Immunity for Health Care Providers Working with Pregnant Women.</h3>
                <p>A health care provider may not be subject to disciplinary action by the professional licensing board that licenses the health care provider for following the requirements for prenatal HIV testing established by the Department.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.08.12" data-order="|10|18|08|.12|" data-ref-path="10|18|08|.12" class="h__section">.12 Health Care Providers, First Responders, and Public Safety Workers — HIV Exposure.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.12#A">A.</span> Definition.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.12#A(1)">(1)</span> In this regulation, the following term has the meaning indicated.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.12#A(2)">(2)</span> “Infection preventionist or employee health provider” means the designated infectious disease/communicable disease officer of a hospital.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.12#B">B.</span> A health care provider, first responder, or public safety worker involved in an exposure as defined in Health-General Article, §18-338.3, Annotated Code of Maryland, shall comply with the provisions of Health-General Article, §18-338.3, Annotated Code of Maryland.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.12#C">C.</span> A hospital’s designated infection preventionist or employee health provider or its designee shall follow the requirements in Health-General Article, §18-338.3, Annotated Code of Maryland, if an exposure, as defined in Health-General Article, §18-338.3, Annotated Code of Maryland:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.12#C(1)">(1)</span> Occurs:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.12#C(1)(a)">(a)</span> In a hospital, between a patient and a health care provider; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.12#C(1)(b)">(b)</span> Before admission of the patient to a hospital, between a patient and a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.12#C(1)(b)(i)">(i)</span> First responder; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.18.08.12#C(1)(b)(ii)">(ii)</span> Public safety worker; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.12#C(2)">(2)</span> Is such that, in accordance with the CDC’s recommendations, warrants recommending or offering chemoprophylaxis treatment for the health care provider, first responder, or public safety worker.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h3 id="/us/md/exec/comar/10.18.08.13" data-order="|10|18|08|.13|" data-ref-path="10|18|08|.13" class="h__section">.13 Information on Exposures.</h3>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.13#A">A.</span> A hospital where an exposure occurred shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.13#A(1)">(1)</span> Maintain a confidential record or incident report for an HIV test conducted under <a class="internal-link " href="/us/md/exec/comar/10.18.08.12" title=".12 Health Care Providers, First Responders, and Public Safety Workers — HIV Exposure.">Regulation .12 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.13#A(2)">(2)</span> Adopt procedures for the confidential HIV testing of blood samples or other body fluids used or collected for purposes of <a class="internal-link " href="/us/md/exec/comar/10.18.08.12" title=".12 Health Care Providers, First Responders, and Public Safety Workers — HIV Exposure.">Regulation .12 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.13#A(3)">(3)</span> Maintain a record of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.13#A(3)(a)">(a)</span> An exposure as defined by Health-General Article, §18-338.3(a), Annotated Code of Maryland; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.18.08.13#A(3)(b)">(b)</span> A refusal to consent by a patient as described in the Health-General Article, §18-338.3(b)(2)(ii), Annotated Code of Maryland; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.18.08.13#A(4)">(4)</span> Provide records as specified in §A(3)of this regulation or information from the records to the Department when and as requested by the Secretary.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.18.08.13#B">B.</span> Nothing in <a class="internal-link " href="/us/md/exec/comar/10.18.08.12" title=".12 Health Care Providers, First Responders, and Public Safety Workers — HIV Exposure.">Regulation .12 of this chapter</a> or this regulation shall be construed to exempt any individual or entity required to report infectious diseases from reporting the infectious diseases as required in Health-General Article, Title 18, Annotated Code of Maryland.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.18.09" data-order="|10|18|09|" data-ref-path="10|18|09" class="h__chapter">Chapter 09 HIV Testing for Pregnant Women Receiving Prenatal Care</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: August 28, 2006 (33:17 Md. R. 1437)</p>
                  <p>Regulation .01A amended effective December 14, 2009 (36:25 Md. R. 1954)</p>
                  <p>Regulation .01F adopted effective December 14, 2009 (36:25 Md. R. 1954)</p>
                  <p>Regulation .02B amended effective December 14, 2009 (36:25 Md. R. 1954)</p>
                  <p>Regulation .03 amended effective December 14, 2009 (36:25 Md. R. 1954)</p>
                  <p>Regulation .04 amended effective December 14, 2009 (36:25 Md. R. 1954)</p>
                  <p>Regulation .05 amended effective December 14, 2009 (36:25 Md. R. 1954)</p>
                  <p>Regulation .07B amended effective December 14, 2009 (36:25 Md. R. 1954)</p>
                  <p>——————</p>
                  <p>Chapter revised effective March 27, 2017 (44:6 Md. R. 326)</p>
                  <p>——————</p>
                  <p>Chapter repealed effective May 7, 2018 (45:9 Md. R. 462)</p>
                </section>
                <h2 id="/us/md/exec/comar/10.18.10" data-order="|10|18|10|" data-ref-path="10|18|10" class="h__chapter">Chapter 10 Urgent Maryland AIDS Drug Assistance Program</h2>
                <section class="line-group annotations">
                  <h3>Administrative History</h3>
                  <p>Effective date: March 28, 2016 (43:6 Md. R. 408)</p>
                  <p>Regulation .02B amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p>Regulation .03B amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p>Regulation .04 amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p>Regulation .05B amended effective May 20, 2019 (46:10 Md. R. 488)</p>
                  <p>——————</p>
                  <p>Regulations .01—.09 repealed effective June 13, 2022 (49:12 Md. R. 640)</p>
                </section>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/10.17" aria-label="Subtitle 17 SWIMMING POOLS AND SPAS">
                <div class="h__ui">Previous</div>
                <span>Subtitle 17 SWIMMING POOLS AND SPAS</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/10.19" aria-label="Subtitle 19 DANGEROUS DEVICES AND SUBSTANCES">
                <div class="h__ui">Next</div>
                <span>Subtitle 19 DANGEROUS DEVICES AND SUBSTANCES</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">
<p>This version of the laws and codes on this website is licensed under the <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/">CC BY-NC-SA 4.0</a> license with copyright held by the State of Maryland.</p><p>This version of the laws and codes on this website will be dedicated to the public domain under the <a href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0</a> license 180 days after publication.</p>
<p>
      Please do not scrape. Instead, bulk download the CC BY-NC-SA-4.0 <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a> or CC0 <a href="https://github.com/maryland-dsd/law-html-cc0">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml-cc0">XML</a>.
    </p><p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p></div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
